fhoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche finance report finance report finance brief key result sale core operate profit margin cer growth sale pharmaceutical diagnostic group change sale chf chf chf cer ifrs result sale operating profit net income net income attributable roche shareholder dilute eps chf dividend share chf core result research development core operating profit core eps chf free cash flow operate free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant exchange rate average rate year end december core result core ep earning share exclude noncore item global restructuring plan amortisation impairment goodwill intangible asset allow transparent assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result give cover run stringent control medicine ensure product provide patient meet respective production criterion stefan kamber inprocesscontrol expert roche solid production unit basel conduct multiple check cotellic new cancer medicine approve fda european commission november finance brief roche roche group report strong overall result sale grow constant exchange rate cer core earning share increase exclude impact onetime income divestment filgrastim franchise right underlie core earning grow sale group sale increase cer chf billion growth chf term pharmaceutical sale growth cer continue strong growth franchise avastin oncology portfolio immunology sale esbriet actemraroactemra increase sale pegasys decrease competition new generation treatment valcytecymevene xeloda decrease generic competition diagnostic sale show growth cer professional diagnostic major contributor operating result core operating profit increase cer chf billion decline chf term exclude onetime income divestment filgrastim franchise right underlie core operating profit grow research development expenditure grow cer chf billion core basis focus oncology immunology neuroscience therapeutic area research development cost group sale ifrs operating result include noncore expense chf billion major factor chf billion amortisation intangible asset chf billion global restructuring plan notably pharmaceutical division strategic realignment manufacturing network nonoperate result core net financial expense increase chf billion chf billion drive low income divestment equity security ifrs net financial expense additionally include loss chf billion major debt restructure net income ifrs net income increase cer chf billion decline chf term core earning share increase cer chf term exclude onetime income divestment filgrastim franchise right underlie earning share grow cash flow operate free cash flow chf billion decrease cer chf term growth operating profit offset high capital investment low increase account payable free cash flow decrease cer chf term chf billion drive operating free cash flow decline high tax dividend payment acquisition notably majority stake foundation medicine ariosa kapa acquisition diagnostic sequence business utilise total chf billion cash financial position net work capital decrease cer increase payable end net debt stable chf billion free cash flow largely absorb acquisition net debt percentage total asset credit rating strong moodys standard poor shareholder return dividend proposal increase dividend chf share represent consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr represent combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statement note roche group consolidate financial statement general accounting principle noncurrent liability operate segment information current liability net financial expense provision contingent liability income taxis debt business combination equity attributable roche shareholder global restructuring plan subsidiarie property plant equipment noncontrolle interest goodwill employee benefit intangible asset pension postemployment benefit inventory equity compensation plan account receivable earning share nonvoting equity security marketable security statement cash flow cash cash equivalent risk management noncurrent asset relate party current asset subsidiary associate account payable significant accounting policy report roche management internal control financial reporting report statutory auditor general meeting shareholder roche holding ltd basel report independent auditor internal control financial reporting board director roche holding ltd basel multiyear overview supplementary information roche security roche holding ltd basel financial statement note financial statement appropriation available earning report statutory auditor general meeting shareholder roche holding ltd basel financial review roche group financial review roche group result sale billion chf core operating profit billion chf cer growth sale net income attributable roche shareholder billions chf core eps chf roche group result show sale growth core operate profit growth constant exchange rate cer sale increase drive oncology immunology portfolio especially medicine herpositive breast cancer professional diagnostic business core eps grow low rate sale base effect onetime income divestment filgrastim franchise right exclude item core operating profit core eps grow ahead sale operate free cash flow chf billion sale decrease cer increase capital expenditure investment intangible asset high increase net work capital sale pharmaceutical division rise chf billion increase drive oncology portfolio especially franchise grow avastin sale higher increase use recently launch indication sale immunology grow actemraroactemra xolair increase respectively strong uptake esbriet follow launch sale pegasys decline competition new generation treatment sale valcyte cymevene xeloda fall generic competition tamiflu sale fall relatively mild influenza season region show growth pharmaceutical sale significant diagnostic sale grow chf billion securing division lead market position major growth area professional diagnostic sale increase lead immunodiagnostic business molecular diagnostic tissue diagnostic increase respectively sale diabetes care decrease continued challenging market environment core operating profit increase pharmaceutical division fall diagnostic division pharmaceutical division growth underlie business compensate base effect divestment income chf million filgrastim franchise right exclude item core operating profit pharmaceutical increase manufacturing cost high capacity expansion source strategy biologic high inventory writeoff marketing distribution cost grow launch rollout new product notably recently acquire product esbriet research development continue investment oncology immunology inflammation respiratory therapeutic area diagnostic core operating profit low mainly high sale offset cost sequence business increase research development cost professional diagnostic diabetes care performance impact price erosion major market operate free cash flow chf billion decrease cer chf term continuous strong operating cash generation offset capital investment manufacturing facility site development project notably switzerland germany increase level inlicense activity low increase account payable free cash flow chf billion decrease relative mainly drive low operate free cash flow high tax payment high annual dividend payment roche finance report roche group financial review ifrs net income grow cer compare increase core net income addition item describe core result ifrs result include base effect impairment goodwill intangible asset year chf billion net tax swiss franc appreciate number currency particular euro japanese yen latin american european currency effect partly offset strong dollar relative average rate overall impact negative growth rate express swiss franc compare constant exchange rate percentage point impact sale percentage point impact core operating profit percentage point impact core ep currency translation sensitivity group result movement foreign currency exchange rate include income statement change change chf chf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest eps basic chf eps diluted chf core result sale royalty operate income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core ep basic chf core eps diluted chf roche finance report financial review roche group sale sale increase cer chf usd chf billion sale pharmaceutical division rise chf billion drive growth medicine herpositive breast cancer avastin esbriet mabtherarituxan actemraroactemra avastin sale grew drive increase use recently launch indication immunology strong uptake esbriet follow launch late subcutaneous formulation actemraroactemra sale xolair increase pharmaceutical sale increase region particularly franchise grow sale pegasys decline competition new generation treatment valcytecymevene xeloda sale decline product offpatent xeloda additionally offpatent europe tamiflu sale fall relatively mild influenza season late compare severe influenza season comparative period sale lucentis decline strong competition diagnostic division sale chf billion increase cer division retain lead market position major growth area professional diagnostic represent half division sale grow lead immunodiagnostic business sale molecular diagnostic tissue diagnostic increase respectively diabetes care sale decrease continue reimbursement cut pricing pressure divisional operating result pharmaceutical diagnostic corporate group chf chf chf chf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale divisional operating result development result compare pharmaceutical diagnostic corporate group sale increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operate free cash flow increase cer margin percentage point increase core operating result pharmaceutical division division core operating profit increase cer line sale increase cost growth contain line increase sale low royalty operating income drive oneoff income chf million divestment filgrastim franchise right exclude income division core operating profit grow diagnostic division core operating profit cer compare sale increase increase cost recently acquire company sequence business offset growth underlie business diabete care impact price erosion major market like roche finance report roche group financial review acquisition roche group complete acquisition company include previously announce total cost acquire net asset chf billion cash chf billion fair value contingent consideration arrangement april pharmaceutical division acquire control interest foundation medicine fmi usd billion transaction advance fmis marketleading position molecular information genomic analysis provide group unique opportunity optimise identification development novel treatment option cancer patient pharmaceutical division complete acquisition trophos diagnostic division acquire geneweave bioscience molecular diagnostic sequence business ariosa diagnostic signature diagnostic capp medical kapa biosystem september pharmaceutical division acquire control interest intermune usd billion acquisition add new medicine idiopathic pulmonary fibrosis esbriet roche portfolio noncore cost relate intermune include intangible asset amortisation chf billion expense chf million release inventory fair value adjustment group issue usd billion debt finance transaction annual financial statement account intermune dutalys bina acquisition provisional base preliminary information valuation asset liability valuation finalise result comparative balance sheet information december restate contingent consideration provision increase chf million chf billion mainly new provision chf million arise acquisition addition net increase provision chf million record general administration expense mainly progression lead product candidate seragon acquisition partially offset payment chf million mainly related iquum acquisition detail give note annual financial statement global restructuring plan group continue implementation major global restructuring plan initiate prior year notably programme diagnostic division diabetes care business november pharmaceutical division announce strategic realignment manufacturing network include exit site total cost chf billion considerably high cost chf billion strategic realignment pharmaceutical division manufacturing network cost chf billion global restructuring plan cost incur millions chf diagnostic site consolidation plan total global restructuring cost employeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost include diabete care autonomy speed restructuring plan include pharmaceutical division strategic realignment manufacturing network include plan pharmaceutical division research development strategic realignment field force reduction europe asiapacific roche finance report financial review roche group diagnostic division september roche diabetes care announce autonomy speed initiative enable business focus diabete care specific requirement speed process decisionmake drive efficiency cost chf million incur mainly consultancy itrelate cost employeerelate cost spend small plan division chf million include cost relate certain project restructure apply science business site consolidation november pharmaceutical division announce strategic realignment manufacturing network include exit manufacture site clarecastle ireland legans spain segrate italy florence cost plan expect order chf billion chf billion cash plan expect run approximately position affect cost plan chf million chf million noncash writedown accelerate depreciation property plant equipment additional cost record pharmaceutical division outsource logistics rosny site france closure manufacturing site toluca mexico divestment plans nutley site track global restructuring plan major item chf million pharmaceutical division research development strategic realignment chf million initiative reduce field force europe asiapacific region detail give note annual financial statement impairment goodwill intangible asset minor impairment pharmaceutical division impairment charge total chf million relate decision stop development compound collaboration project different alliance partner impairment diagnostic division total impairment charge record goodwill intangible asset chf billion major tissue diagnostic business impairment charge chf million goodwill chf million product intangible asset detail give note annual financial statement legal environmental settlement legal environmental settlement include provision chf million remediation cost clarecastle production site ireland follow strategic realignment pharmaceutical division manufacture network significant development detail give note annual financial statement major debt restructuring result attractive financing condition capital market group decide september restructure debt consist refinance usd billion note coupon originally eur billion note coupon originally issuance usd billion note coupon major debt restructuring result loss chf million detail give note annual financial statement treasury taxation core financing cost chf billion decrease mainly loss debt redemption interest cost low core financial expense chf million reflect net foreign exchange loss chf million mainly arise venezuela argentina partially offset chf million net income equity security core tax expense increase chf billion group effective core tax rate increase compare mainly high percentage core profit contribution come tax jurisdiction high local tax rate average group tax rate notably roche finance report roche group financial review net income earning share ifrs net income dilute eps decrease chf term cer ifrs income increase dilute eps increase core net income increase core eps increase cer core basis exclude noncore item global restructuring cost amortisation impairment goodwill intangible asset alliance business combination cost exclude income divestment filgrastim franchise right chf million related tax effect chf million underlying core ep grow cer net income change change chf chf chf cer ifrs net income reconcile item net tax global restructure intangible asset amortisation goodwill intangible asset impairment alliance business combination legal environmental settlement major debt restructure pension plan settlement normalisation tax benefit equity compensation plan core net income supplementary net income ep information give page include calculation core eps reconcile core result group publish ifrs result financial position financial position change change chf chf chf cer pharmaceutical net work capital longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operating asset net debt pension income taxis nonoperate asset net total net asset disclose note annual financial statement balance sheet december restate follow finalisation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish balance sheet provide note roche finance report financial review roche group compare start swiss franc appreciate currency notably euro brazilian real result overall negative translation impact balance sheet position dollar end year rate swiss franc begin year little translation impact balance sheet position exchange rate give pharmaceutical division net working capital decrease cer increase payable end exercise purchase option office south san francisco addition trade receivables decrease mainly consequence low tamiflu sale end good collection inventory level rise expansion production capacity include delivery external manufacturing partner high sale volume new establish product longterm net operating asset increase result goodwill intangible asset foundation medicine trophos acquisition high capital expenditure purchase option exercise office south san francisco diagnostic increase net work capital result strong sale performance challenging political economic situation result increase inventory account receivables longterm net operating asset increase intangible asset goodwill acquisition net debt stable chf billion free cash flow largely absorb acquisition net pension liability decrease chf billion main driver translation eurodenominate unfunded plan germany swiss franc consolidation net tax liability increase mainly defer tax effect acquisition accounting free cash flow free cash flow change change chf chf chf cer pharmaceutical diagnostic corporate operating free cash flow treasury activity taxis pay dividend pay free cash flow group operate free cash flow chf billion decrease cer chf term operate cash generation absorb high investment property plant equipment site infrastructure office development project expansion manufacturing facility increase inlicense arrangement pharmaceutical division free cash flow chf billion decrease significantly compare relatively low operate free cash flow high tax payment increase annual dividend roche finance report roche group financial review pharmaceutical division operating result pharmaceutical division operating result change change chf chf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core ep sale overview pharmaceutical division sale therapeutic area change sale sale therapeutic area chf chf cer oncology immunology infectious disease ophthalmology neuroscience therapeutic area total sale pharmaceutical division sale increase cer strong growth oncology immunology product sale growth primarily drive follow product herceptin avastin perjeta esbriet mabtherarituxan actemraroactemra kadcyla product contribute chf billion cer sale growth growth franchise result increase demand perjeta herceptin combination therapy continue uptake kadcyla avastin sale grow region drive increase use recently launch indication mabthera rituxan sale increase notably sale immunology increase demand esbriet follow launch late growth actemraroactemra region subcutaneous formulation xolair grow increase uptake recently launch indication chronic idiopathic urticaria roche finance report financial review roche group sale pegasys decline competition new generation treatment sale valcytecymevene xeloda fall generic competition tamiflu sale low relatively mild influenza season late compare severe season late sale lucentis decline strong competition product sale pharmaceutical division sale change sale sale chf chf cer oncology avastin herceptin mabtherarituxan perjeta tarceva kadcyla xeloda zelboraf total oncology immunology actemraroactemra mabtherarituxan xolair cellcept pulmozyme esbriet total immunology infectious disease tamiflu pegasys valcytecymevene rocephin total infectious disease ophthalmology lucentis total ophthalmology neuroscience madopar total neuroscience therapeutic area activasetnkase mircera neorecormonepogin nutropin total therapeutic area total sale total mabtherarituxan sale chf million chf million split oncology immunology franchise roche finance report roche group financial review mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukemia cll follicular lymphoma rheumatoid arthritis certain type ancaassociate vasculitis mabtherarituxan regional sale change sale sale chf chf cer united states europe japan international total sale sale higher drive primarily strong growth oncology immunology sale international region grow drive growth eastern europe middle east africa subregion public sector sale latin america sales europe increase mainly france italy franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin herceptin regional sale change sale sale chf chf cer united states europe japan international total sale perjeta regional sale change sale sale chf chf cer united states europe japan international total sale kadcyla regional sale change sale sale chf chf cer united states europe japan international total sale overall growth franchise herceptin sale grow continue strong growth result long duration treatment combination perjeta early advanced breast cancer demand international region grow strongly growth subregion europe sale stable perjeta grow region particularly europe approve use surgery early stage aggressive breast cancer kadcyla sale double europe reimbursement grant italy france spain sale increase international region japan roche finance report financial review roche group avastin advanced colorectal breast lung kidney cervical ovarian cancer relapse glioblastoma type brain tumour avastin regional sale change sale sale chf chf cer united states europe japan international total sale demand avastin strong sale growth region sale grew drive expand use recently launch indication cervical ovarian cancer europe sale grow result increase treatment ovarian colorectal lung cervical cancer international region growth drive mainly phase delivery public sector approval new indication japan sale increase increase demand use breast lung cancer lucentis wet agerelate macular degeneration amd macular edema follow retinal vein occlusion rvo diabetic macular edema dme lucentis regional sale change sale sale chf chf cer united states total sale sale lucentis decline competition wet amd dme segment february lucentis approve additional indication diabetic retinopathy people dme actemraroactemra rheumatoid arthritis systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis actemraroactemra regional sale change sale sale chf chf cer united states europe japan international total sale sale increase growth region notably europe drive strong demand subcutaneous formulation represent total actemraroactemra sale increase demand early treatment rheumatoid arthritis monotherapy xolair moderate severe persistent allergic asthma chronic idiopathic urticaria ciu xolair regional sale change sale sale chf chf cer united states total sale sale increase high prescription asthma strong uptake new indication chronic idiopathic urticaria approve march roche finance report roche group financial review tarceva advanced nonsmall cell lung nsclc pancreatic cancer tarceva regional sale change sale sale chf chf cer united states europe japan international total sale sale low decline sale europe international region increase competitive pressure esbriet idiopathic pulmonary fibrosis ipf esbriet regional sale change sale sale chf chf cer united states europe japan international total sale strong uptake esbriet follow approval fda late sales europe drive germany italy pegasys hepatitis pegasys regional sale change sale sale chf chf cer united states europe japan international total sale sale decrease region increase competition new generation hepatitis therapie tamiflu influenza tamiflu regional sale change sale sale chf chf cer united states europe japan international total sale sale decline mainly relatively mild influenza season quarter contrast severe epidemic influenza season end sale decrease europe mainly low governmental sale pandemic stockpiling compare japan high seasonal demand fourth quarter roche finance report financial review roche group pharmaceutical division sale region change sale sale region chf chf cer united states europe japan international eemea latin america asiapacific region total sale eastern europe middle east africa united states sale grew lead breast cancer franchise lead product oncology medicine mabtherarituxan avastin herceptin sale chf billion chf billion chf billion respectively addition strong demand esbriet xolair growth negatively impact sharp decline valcytecymevene xeloda offpatent lucentis pegasys increase competition europe sale increase continued strong growth breast cancer franchise good uptake esbriet addition continue sale growth actemraroactemra avastin growth partially offset low pegasys tarceva sale tamiflu sale lower mainly pandemic stockpile japan sale grow major growth driver avastin franchise newly launch alecensa alectinib avastin sale grow increase demand approve indication particular use breast lung cancer alecensa alkpositive nonsmall cell lung cancer nsclc launch japan september sales chf million sale osteoporosis medicine edirol increase international sale increase drive latin america subregion growth latin america mainly franchise oncology product especially avastin mabtherarituxan actemraroactemra sale increase significantly sale pegasys xeloda decline asiapacific main driver growth herceptin avastin mabtherarituxan herceptin growth result significant activity ensure patient access medicine china total sale key emerge market grow strong volume growth brazil drive market access activity new product launch offset price decrease pharmaceutical division sale lead emerge market change sale sale country chf chf cer brazil china india mexico russia south korea turkey total sale roche finance report roche group financial review operating result pharmaceutical division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product total ifrs core basis decrease cer low income product disposal partly offset high outlicense income income fall comparative period include chf million income sale filgrastim franchise right amgen exclude item growth royalty income stable receipt certain nonrecurring royalty offset low royalty lucentis enbrel increase outlicense income upfront milestone payment exclusive licence agreement galenica commercialisation mircera payment collaboration partner deblocke amendment pharmaceutical division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset business combination inventory fair value adjustment total ifrs basis core cost increase cer percentage sale cost sale increase percentage point increase manufacturing cost good sell period cost result mainly biologic manufacturing capacity increase source strategy addition inventory writedown increase chf million royalty expense low tamiflu sale expense collaboration profitshare agreement increase mainly drive high copromotion expense grow sale mabtherarituxan xolair noncore cost include chf million strategic realignment manufacturing network amortisation intangible asset intermune acquisition release inventory fair value adjustment pharmaceutical division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis core cost increase cer percentage sale fall additional cost incur market esbriet follow launch late ensure increase patient access medicine franchise marketing effort continue support establish launch product restructuring cost relate productivity initiative mainly asia europe outsourcing logistic rosny site france pharmaceutical division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis roche finance report financial review roche group core cost increase cer percentage sale increase oncology franchise remain primary area research development investment advancement cancer immunotherapy treatment activity increase immunology inflammation respiratory area drive programme asthma inflammatory bowel disease idiopathic pulmonary fibrosis addition pharmaceutical division spend chf million inlicense pipeline compound technology capitalise intangible asset global restructuring cost mainly result pharmaceutical division research development strategic realignment notably transfer oncology discovery penzberg germany zurich switzerland impairment charge chf million result decision stop development compound different alliance partner decision stop collaboration project alliance partner pharmaceutical division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment business taxis capital taxis general item general administration core basis global restructuring plan impairment goodwill alliance business combination legal environmental settlement pension settlement gain loss total ifrs basis core cost decrease cer base effect onetime double charge brand prescription drug fee operating profit impact chf million percentage sale cost fall administration cost decrease low management cost alliance business combination cost relate mainly additional contingent consideration provision record respect seragon acquisition note annual financial statement legal environmental settlement include provision chf million remediation cost clarecastle production site ireland pharmaceutical division strategic manufacturing realignment noncore cost include impairment goodwill marcadia acquisition follow exit cardiovascular metabolic disease impairment dedicated goodwill relate certain previous acquisition roche pharmaceutical chugai subdivisional operating result pharmaceutical subdivisional operating result million chf roche pharmaceutical pharmaceutical chugai division sale external customer division core operate profit margin sale external customer operate profit margin sale external customer operate free cash flow margin sale pharmaceutical division total core operating profit operating profit include elimination chf million chf million unrealised intercompany profit roche pharmaceutical chugai fall exchange rate japanese yen negative impact approximately percentage point chugais sale growth percentage point core operate profit growth express swiss franc compare growth rate japanese yen sale external customer chugai increase japanese yen sale roche chugai significantly high resulted increase chugai core operating profit increase chugais operating profit margin additional revenue flow increase operating profit chugais operate free cash flow increase increase revenue low trade receivables result time sale improve customer payment term roche finance report roche group financial review financial position pharmaceutical division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivablespayable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset disclose note annual financial statement balance sheet december restate follow finalisation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish balance sheet provide note absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start swiss franc appreciate currency notably euro brazilian real result overall negative translation impact net operating asset dollar end year rate swiss franc begin year little translation impact balance sheet position exchange rate give net work capital decrease cer mainly increase payable end exercise purchase option office south san francisco trade receivables decrease compare end mainly low tamiflu sale end good collection decrease inventory release noncash intermune inventory fair value adjustment offset increase inventory level expansion production capacity include delivery external manufacturing partner inventory level rise support sale volume increase new establish product longterm net operating asset increase mainly significant addition property plant equipment goodwill intangible asset result acquisition foundation medicine trophos property plant equipment increase investment continue site infrastructure office development project expansion manufacturing facility particular switzerland germany property plant equipment increase follow exercise purchase option office south san francisco increase provision result mainly high contingent consideration provision seragon acquisition new restructuring provision strategic realignment manufacture network roche finance report financial review roche group free cash flow pharmaceutical division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale detail breakdown provide pharmaceutical division operate free cash flow decrease chf billion operating profit net operating cash adjustment decrease cer strong operating performance offset high capital expenditure increase level inlicensing transaction lead decline operate free cash flow increase net work capital mainly low increase account payable roche finance report roche group financial review diagnostic division operating result diagnostic division operating result change change chf chf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core ep sale diagnostic division continue increase sale growth cer chf billion professional diagnostic sale growth main growth contributor lead immunodiagnostic business molecular diagnostic sale increase growth underlie molecular business genome sequence business sale double diabete care sale decrease continued challenging market environment notably growth tissue diagnostic drive advanced stain product portfolio diagnostic division sale business area change sale sale business area chf chf cer professional diagnostic diabetes care molecular diagnostic tissue diagnostic total sale roche finance report financial review roche group professional diagnostic increase sale business area major contributor divisional performance region growth primarily drive immunodiagnostic business represent divisional sale support clinical chemistry coagulation monitor business professional diagnostic business grow region especially asiapacific strong sale china growth report europe middle east africa emea region mainly immunodiagnostic clinical chemistry business professional diagnostic regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale improve version cobas troponin test launch june use prehospital emergency care setting diabetes care sale decrease mainly challenge market condition blood glucose monitor portfolio major market like sales accuchek mobile grow lance device sale sale growth outweigh negative impact phaseout old product accuchek advantage accuchek compact accuchek avivaperforma decrease insulin delivery system id business grow drive infusion system newly launch accuchek insight system sale north america mainly spillover medicare price commercial plan reimbursement change canada large province sale emea region decrease increase sale germany nordics middle east offset low sale russia algeria sale grow latin america asiapacific region mainly drive argentina brazil india diabetes care regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale progress implementation specific initiative roche diabetes care start goal streamline process decisionmake drive efficiency continue develop innovative solution molecular diagnostic sale rise growth underlie molecular business major contribution come virology hpv cervical cancer screen genomic oncology business partly offset sale decline blood screening business sale sequence business drive nipt noninvasive prenatal testing contribute overall growth regional growth drive emea increase sale come germany south africa turkey sale grow north america strong sale molecular diagnostic regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale roche finance report roche group financial review tissue diagnostic sale rise drive growth advance stain portfolio companion diagnostic sale grow regionally growth drive north america emea region growth drive advanced staining portfolio sale asiapacific grow china main market revenue exist external partnership show continue growth tissue diagnostic regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale diagnostic division sale region change sale sale region chf chf cer europe middle east africa emea north america asiapacific latin america japan total sale sale growth diagnostic division drive asiapacific emea region mainly professional diagnostic sale increase asiapacific mainly drive increase sale china result governmental healthcare investment public demand division expand presence wide portfolio emea region division large market sale increase lead growth professional diagnostic molecular diagnostic sale latin america region increase drive professional diagnostic diabetes care sale japan remain stable high sale professional diagnostic compensate low molecular diagnostic sale diagnostic division sale lead emerge market change sale sale country chf chf cer brazil china india mexico russia south korea turkey total sale operating result diagnostic division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product total ifrs core basis royalty income increase cer royalty payment professional diagnostic roche finance report financial review roche group diagnostic division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer primarily increase period cost drive high technical service cost startup validation cost additional depreciation thirdparty instrument support growth emerge market cost sale ratio stable global restructuring cost incur mainly ongoing autonomy speed project diabetes care initiative harmonise process system diagnostic diagnostic division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis core cost increase cer reflect high spend professional diagnostic sequence business particularly market support sale force increase spending mainly drive asiapacific emea region high allowance doubtful receivables southern europe core basis marketing distribution cost percentage sale compare global restructuring cost mainly reorganisation diabetes care business diagnostic division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer drive increase spend major project professional diagnostic investment sequence business percentage sale research development core cost increase comparative period include chf million intangible asset impairment relate tissue diagnostic business area diagnostic division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment business taxis capital taxis general item general administration core basis global restructuring plan impairment goodwill intangible asset alliance business combination legal environmental settlement pension settlement gain loss total ifrs basis roche finance report roche group financial review core cost decrease cer administration expense grow drive organisational structure sequence business include new acquisition percentage sale core cost decrease comparative period include chf million goodwill impairment relate tissue diagnostic business area financial position diagnostic division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivablespayable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset disclose note annual financial statement balance sheet december restate follow finalisation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish balance sheet provide note absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start swiss franc appreciate currency notably euro result overall negative translation impact net operating asset diagnostic division significant net asset position euro appreciation swiss franc euro major impact dollar end year rate swiss franc begin year little translation impact balance sheet position exchange rate give net work capital net trade working capital increase cer inventory increase high demand emerge market notably brazil mexico china trade payables increase result improve payment term supplier trade receivable increase sale growth few factoring initiative southern europe longterm net operating asset increase cer increase intangible asset goodwill ariosa signature capp medical geneweave kapa biosystem acquisition inlicense arrangement property plant equipment increase manufacturing site expansion germany headquart development switzerland provision increase contingent consideration provision arise acquisition roche finance report financial review roche group free cash flow diagnostic division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale detail breakdown provide operate free cash flow diagnostic division decrease chf billion cash generation business offset increase net working capital note comment financial position property plant equipment increase instrument placement site development germany switzerland increase investment intangible asset come inlicense arrangement corporate operating result corporate operating result summary change chf chf cer administration business taxis capital taxis general item general administration cost core basis global restructuring plan legal environmental settlement total cost ifrs basis financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow page definition core result core eps general administration cost stable cer change net operating asset mainly utilisation provision remediation activity nutley grenzach germany corporate operating free cash flow show high outflow mainly utilisation provision roche finance report roche group financial review foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report cer chf change cer change chf pharmaceutical division sale core operate profit diagnostic division sale core operating profit group sale core operating profit exchange rate swiss franc december average december average usd eur jpy compare swiss franc strong currency particular euro japanese yen latin american european currency dollar appreciation partially offset negative impact sale development result negative growth impact percentage point equivalent chf billion translate swiss franc currency translation loss operate profit growth percentage point mainly drive depreciation euro january swiss national bank snb announce discontinue minimum exchange rate swiss franc euro consequence stock market switzerland fall significantly value swiss franc increase roche group fundamental impact foresee example group incur overall cost switzerland token key market europe japan complete value chain mean cost incur local currency swiss franc note annual financial statement group use swiss franc presentation currency annual financial statement weaken foreign currency swiss franc negative currency translation impact group consolidated result report swiss franc sensitivity group sale core operating profit change average foreign currency exchange rate swiss franc show table currency sensitivity impact change average exchange rate sale core operating profit versus swiss franc chf chf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost mainly concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany chugais revenues cost denominate japanese yen roche finance report financial review roche group treasury taxation result treasury taxation result change change chf chf chf cer ifrs result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest financial position treasury taxation net debt pension income taxis financial noncurrent asset derivative net collateral net interest payable nonoperate asset net total net asset liability free cash flow treasury taxation treasury activity taxis pay dividend pay total page definition core result core ep financing cost finance cost ifrs basis low cer mainly high loss debt redemption low interest expense core financing cost chf million decrease chf million cer compare interest expense decrease continue repayment debt despite new debt issue intermune acquisition loss early redemption debt chf million compare chf million net interest cost define benefit pension plan decrease chf million low discount rate partially offset decrease funding status end group restructure debt result loss repurchase chf million analysis financing cost give note annual financial statement detail major debt restructuring repayment redemption give note roche finance report roche group financial review financial income expense core financial income expense net expense chf million compare net income chf million net income equity security chf million chf million comparative period net foreign exchange result reflect hedging cost loss unhedged position net foreign exchange loss period chf million compare net loss chf million period result include loss chf million venezuela chf million argentina analysis financial income expense give note annual financial statement income taxis group effective core tax rate increase percentage point mainly high percentage core profit contribution come tax jurisdiction high local tax rate average group tax rate notably analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate chf chf chf chf group effective tax rate core basis global restructuring plan goodwill intangible asset alliance business combination legal environmental major debt restructuring normalisation tax benefit equity compensation plan group effective tax rate ifrs basis financial position net debt position remain stable net pension liability decrease translation eurodenominate obligation group plan germany net tax liability increase mainly defer tax effect newly acquire company interest payable relate bond note coupon payment date march september decline chf billion coupon payment bond note partly offset interest accrue period december group hold financial longterm asset market value chf billion consist holding biotechnology company acquire context licensing transaction scientific collaboration dollar end year rate swiss franc begin year little translation impact group dollardenominate debt translate swiss franc consolidation free cash flow cash outflow treasury activity increase chf billion low proceed sale equity investment partly offset low interest payment total taxis pay chf billion increase tax payment relatively low tax prepayment end total dividend pay chf billion increase chf billion compare reflect increase roche group annual dividend roche finance report financial review roche group cash flow net debt operate free cash flow billion chf free cash flow billion chf free cash flow millions chf pharmaceutical diagnostic corporate group operate profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operating profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operate free cash flow chf billion decrease cer chf term mainly high capital expenditure property plant equipment switzerland germany high investment inlicense arrangement pharmaceutical division increase net work capital cash outflow treasury activity increase mainly low proceed sale equity investment total taxis pay chf billion increase time tax prepayment total dividend pay high increase annual roche group dividend free cash flow chf billion low lower operate free cash flow high tax payment increase dividend roche finance report roche group financial review net debt millions chf december cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow transaction equity instrument business combination net divestment subsidiary hedge collateral arrangement currency translation fair value movement change net debt period december cash cash equivalent marketable security longterm debt shortterm debt net debt end period net debt currency profile millions chf cash marketable security debt dollar euro swiss franc japanese yen pound sterling total dollardenominate debt include bond note denominate euros swiss franc pound sterling swap dollar consolidated result economic characteristic equivalent dollardenominate bond note net debt position group december chf billion increase chf billion december free cash flow chf billion include annual dividend payment chf billion offset net cash outflow chf billion acquisition net outflow chf billion hedging collateral arrangement dollar end year rate swiss franc begin year little translation impact group dollardenominate debt translate swiss franc consolidation group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar time collateral agreement enter derivative counterpartie mitigate counterparty risk cash collateral balance increase chf billion collateral balance relation hedge nonus dollardenominate bond note mainly sensitive foreign exchange rate dollar euro pound sterling currently collateral balance move approximately usd million foreign exchange rate simultaneously issuance redemption repurchase bond note note annual financial statement impact liquid fund impact net debt position roche finance report financial review roche group pension postemployment benefit postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan chf million chf million plan classify define benefit plan group potential obligation minor relatively remote possibility arise plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource define benefit plan expense group define benefit plan chf million chf million increase mainly increase current service cost chf million drive low discount rate begin compare begin base revise actuarial assumption end expense group define benefit plan expect approximately chf million drive high discount rate begin estimate pension expense include settlement past servicecurtailment effect arise year funding status balance sheet position chf chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability overall funding status ifrs basis group fund define benefit plan stable compare start year fund status pension fund monitor local pension fund governance body closely review group level unfunded plan mainly group german affiliate fully reserve pension obligation invest local affiliate operation unfunded liability plan decrease chf billion increase discount rate germany translation eurodenominate unfunded plan germany swiss franc consolidation detail group pension postemployment benefit give note annual financial statement roche finance report roche group financial review roche share share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group consist roche healthcare company total shareholder return tsr define share price growth plus dividend measure swiss franc actual exchange rate constant exchange rate cer roche rank number yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group chf term cer healthcare sector outperform key market sector despite continue price rise political pressure roche share perform line peer constant exchange rate global macroeconomic concern cause major volatility year roche outperform peer chf term swiss market index positive news flow end phase iii result ocrelizumab multiple sclerosis strong quarter sale announcement target upgrade peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source datastream datum roche peer index rebase january peer index convert swiss franc daily actual exchange rate currency fluctuation influence representation relative performance roche versus peer index roche finance report financial review roche group propose dividend board director propose increase dividend chf share nonvoting equity security chf approval annual general meeting consecutive increase dividend dividend proposal approve shareholder dividend payment total share nonvoting equity security chf billion chf billion result payout ratio base core net income base price yearend dividend yield roche share yield nonvoting equity security information roche security give page information share nonvoting equity security change chf chf chf eps basic eps diluted core ep basic core ep diluted equity attributable roche shareholder share dividend share detail refer note annual financial statement payout ratio calculate dividend share divide core earning share debt early partial redemption usd million note originally march redeem march follow exercise earlycall option december redemption date march gbp million note redemption date july usd billion note note redeem follow debt restructuring december group resolve exercise option early redemption usd million note march note repay march result attractive financing condition capital market group decide september restructure debt debt restructuring include redemption usd million note originally march redemption usd million note originally march redemption usd million note originally july redemption eur million note originally march refinance issue usd billion note november major debt restructuring result loss chf million transaction describe note annual financial statement maturity schedule group bond note outstanding december show table bond note nominal amount december contractual maturity dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf total total translate december exchange rate proceed bond note eur billion swap dollar consolidated result bond note economic characteristic equivalent dollardenominate bond note roche finance report roche group financial review group plan meet debt obligation exist liquid fund cash generate business operation free cash flow chf billion include cash generate operation payment interest tax dividend shortterm financing requirement group commercial paper program issue usd billion unsecured commercial paper note commit credit line usd billion available backstop line commercial paper note total usd billion outstanding december december usd billion longerterm financing group maintain strong longterm investmentgrade credit rating standard poor moodys facilitate efficient access international capital market information group debt give note annual financial statement credit rating roche group december shortterm longterm outlook moodys stable standard poor stable financial risk december group net debt position chf billion chf billion financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt redemption liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement cash marketable security chf total chf total cash cash equivalent money market instrument debt security equity security total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group chf billion cash fix income marketable security remain strong invest aaaa range group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position group trade receivables chf billion begin financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country december trade receivables eur billion chf billion public customer country decrease compare december eur term group use different measure improve collection country include intense communication customer forfaite negotiation payment plan charge interest late payment legal action strict commercial policy place select hospital greece italy account hospital spain portugal closely monitor group trade receivable balance southern europe decrease eur term december group trade receivables greece eur million chf million economic situation greece volatile increase credit risk trade receivables group closely monitor situation take appropriate step manage exposure roche finance report financial review roche group liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year roche enjoy strong longterm investmentgrade credit rating standard poor moodys time roche rate high available shortterm rating agency event financing requirement rating strong credit roche permit efficient access international capital market include commercial paper market group commit credit line financial institution total chf billion chf billion serve backstop line commercial paper program december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price group var remain stable interest rate risk interest rate risk arise movement interest rate affect group financial result value group equity group use interest rate derivative manage interestraterelated exposure financial result information financial risk management financial risk var methodology include note annual financial statement international financial reporting standard roche group international financial reporting standard ifrs report consolidated result group implement minor amendment exist standard interpretation material impact group overall result financial position group currently assess potential impact new revise standard interpretation mandatory january group apply base analysis date group anticipate material impact group overall result financial position group assess new revise standard mandatory notably ifrs financial instrument ifrs revenue contract customer ifrs lease roche finance report roche group roche group consolidate financial statement roche group consolidate financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group consolidate financial statement roche group roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidate financial statement roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income remeasurement define benefit plan item reclassify income statement availableforsale investment cash flow hedge currency translation foreign operation item reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total roche finance report roche group consolidate financial statement roche group roche group consolidate balance sheet million chf december december december noncurrent asset property plant equipment goodwill intangible asset defer tax asset define benefit plan asset noncurrent asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer tax liability define benefit plan liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity disclose note balance sheet december restate follow finalisation valuation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish balance sheet provide note roche finance report roche group roche group consolidate financial statement roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease net work capital payment define benefit plan utilisation provision disposal product operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination divestment subsidiary interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement change noncontrolle interest equity contribution noncontrolle interest interest pay dividend pay equitysettle equity compensation plan net transaction equity financing cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december roche finance report roche group consolidate financial statement roche group roche group consolidate statement change equity millions chf non share retain fair value hedge translation control total capital earning reserve reserve reserve total interest equity year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest december year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity business combination change noncontrolle interest equity contribution noncontrolle interest december roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement general accounting principle basis preparation consolidate financial statement annual financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention item require account fair value approve issue board director january subject approval annual general meeting shareholder march financial statement annual financial statement roche holding ltd company register switzerland subsidiary group group significant accounting policy change accounting policy disclose note key accounting judgement estimate assumption preparation annual financial statement require management judgement estimate assumption affect report amount revenue expense asset liability contingent amount actual outcome differ management estimate estimate underlying assumption review ongoing basis base historical experience factor revision estimate recognise period estimate revise follow consider key accounting judgement estimate assumption believe appropriate base currently available information revenue nature group business sale transaction simple structure consist multiple component occur different time group party outlicense agreement involve upfront milestone payment occur year involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement circumstance level sale return revenue reliably measure case sale recognise right return expire generally prescription product patient order estimate management use publicly available information prescription information provide wholesaler intermediary december group chf million provision accrual expect sale return chargeback rebate include medicaid similar rebate country estimate base analyse exist contractual legislatively mandate obligation historical trend group experience december group chf million provision doubtful receivable note estimate base analyse age customer balance specific credit circumstance historical trend group experience take account current economic condition business combination group initially recognise fair value identifiable asset acquire liability assume non control interest consideration transfer business combination management judgement particularly involve recognition fair value measurement intellectual property inventory contingent liability contingent consideration make assessment management consider underlie economic substance item concern addition contractual term roche finance report note roche group consolidate financial statement roche group impairment december group chf million property plant equipment note chf million goodwill note chf million intangible asset note goodwill intangible asset available use review annually impairment property plant equipment intangible asset use assess impairment trigger event provide evidence asset impair assess impairment exist estimate expect future cash flow actual outcome vary significantly estimate factor change discount rate plan use building machinery equipment closure facility presence competition technical obsolescence lower anticipate product sale lead short useful life impairment pension postemployment benefit group operate number define benefit plan fair value recognise plan asset liability base statistical actuarial calculation measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption december present value group define benefit obligation chf million note actuarial assumption differ materially actual result change market economic condition long short life span participant change factor assess difference impact define benefit plan asset liability recognise balance sheet future period legal provision group provide anticipated legal settlement cost probable outflow resource reliably estimate december group chf million legal provision status significant legal case disclose note estimate consider specific circumstance legal case relevant legal advice inherently judgemental highly complex nature legal case estimate change substantially time new fact emerge legal case progress reliable estimate provision record contingent liability disclose material environmental provision group provide anticipate environmental remediation cost probable outflow resource reasonably estimate december group chf million environmental provision note environmental provision consist primarily cost fully clean refurbish contaminate site include landfill treat contain contamination certain site estimate inherently judgemental uncertainty relate detection previously unknown contamination method extent remediation percentage problematic material attributable group remediation site financial capability potentially responsible party estimate change substantially time new fact emerge environmental remediation progress contingent consideration provision group make provision estimate fair value contingent consideration arrangement arise business combination december group chf million contingent consideration provision note total potential payment contingent consideration arrangement chf million note estimate amount provide expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario discount net present value estimate change substantially time new fact emerge scenario develop income taxis december group current income tax net liability chf million defer tax net asset chf million note significant estimate require determine current defer tax asset liability estimate base interpretation exist tax law regulation factor impact current defer taxis include change tax law regulation rate change interpretation exist tax law regulation future level research development spending change pretax earning lease treatment leasing transaction mainly determine lease consider operating finance lease making assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment consolidation group periodically undertake transaction involve obtain control significant influence company transaction include equity acquisition asset purchase alliance agreement transaction structure entity case management make assessment group control significant influence company consolidated subsidiary account associate company make assessment management consider underlie economic substance transaction addition contractual term roche finance report roche group note roche group consolidate financial statement operating segment information group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party residual operating activity divest business certain global activity report corporate include corporate executive committee global group function communication human resource finance include treasury taxis pension fund management legal safety environmental service sub divisional information roche pharmaceutical chugai operate segment pharmaceutical division present divisional information million chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination addition property plant equipment addition intangible asset total research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset inventory fair value adjustment equity compensation plan expense roche finance report note roche group consolidate financial statement roche group pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result operate profit elimination profit division operate profit capital expenditure business combination addition property plant equipment addition intangible asset total research development research development cost elimination cost division total segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset inventory fair value adjustment equity compensation plan expense net operating asset millions chf asset liability net asset pharmaceutical diagnostic corporate total operating nonoperating group disclose note operate asset pharmaceutical diagnostic division nonoperate liability group december restate follow finalisation valuation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish balance sheet provide note roche finance report roche group note roche group consolidate financial statement net operating asset pharmaceutical subdivisional information million chf asset liability net asset roche pharmaceutical chugai elimination division pharmaceutical division disclose note operate asset roche pharmaceutical december restate follow finalisation valuation net asset acquire related intermune dutalys acquisition reconciliation previously publish balance sheet provide note information geographical area millions chf revenue external customer noncurrent asset royaltie property plant goodwill sale operate income equipment intangible asset switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total disclose note goodwill intangible asset europe north america december restate follow finalisation valuation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish balance sheet provide note supplementary unaudited information sale therapeutic area pharmaceutical division business area diagnostic division give financial review sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue roche finance report note roche group consolidate financial statement roche group major customer total national wholesale distributor represent quarter group revenue national wholesale distributor amerisourcebergen corp chf billion chf billion mckesson corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenue pharmaceutical operating segment residual diagnostic segment net financial expense financing cost millions chf interest expense amortisation debt discount net gain loss redemption repurchase bond note loss major debt restructure discount unwind net interest cost define benefit plan total financing cost financial income expense millions chf net gain loss sale equity security net gain loss equity security derivative dividend income writedown impairment equity security net income equity security interest income net gain loss sale debt security net interest income income debt security net foreign exchange gain loss net gain loss foreign currency derivative foreign exchange gain loss net financial income expense associate total financial income expense roche finance report roche group note roche group consolidate financial statement net financial expense million chf financing cost financial income expense net financial expense financial result treasury management financial result pension management associate net financial expense income taxis income tax expense millions chf current income taxis defer taxis total income tax expense group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate group average expect tax rate increase main driver increase high proportion group profit relatively high local tax rate average group rate proportion profit lower goodwill impairment significant local tax rate change main operating area group compare group effective tax rate increase main driver increase high average expect tax rate disclose partially offset tax benefit intragroup transfer intangible right goodwill impairment tax deductible group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect nontaxable incomenondeductible expense equity compensation plan research development tax credit manufacturing deduction state tax impact tax unremitted earning utilisation previously unrecognise tax loss defer tax intragroup transfer difference group effective tax rate income tax benefit record respect equity compensation plan vary accord price underlie equity chf million chf million income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately chf million chf million record roche finance report note roche group consolidate financial statement roche group tax effect comprehensive income millions chf pretax aftertax pretax aftertax tax tax remeasurement define benefit plan availableforsale investment cash flow hedge currency translation foreign operation comprehensive income income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer taxis asset liability net defer tax asset liability disclose note defer tax liability december restate follow finalisation valuation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish balance sheet provide note current income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay business combination charge credit income statement charge credit equity equity compensation plan transaction shareholder currency translation effect movement net current income tax asset liability december roche finance report roche group note roche group consolidated financial statement defer taxis movement recognise net asset liability millions chf property plant intangible define temporary equipment asset benefit plan difference total year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december disclose note net defer tax asset liability december restate follow finalisation valuation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish balance sheet provide note defer tax net asset temporary difference mainly relate accrue liability provision unrealise profit inventory defer tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable chf tax rate chf tax rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer tax liability establish withholding tax taxis payable remittance earning foreign subsidiary amount currently regard permanently reinveste total unremitted earning group regard permanently reinveste chf billion december chf billion roche finance report note roche group consolidate financial statement roche group business combination acquisition acquisition net asset acquire millions chf pharmaceutical diagnostic total intangible asset product intangible use product intangible available use marketing intangible use cash cash equivalent defer tax liability net asset liability net identifiable asset noncontrolle interest fair value previously hold equity interest goodwill total consideration cash contingent consideration total consideration pharmaceutical trophos march group acquire control interest trophos privately own company base marseille france trophos proprietary screening platform generate olesoxime tro develop spinal muscular atrophy sma rare debilitate genetic neuromuscular disease commonly diagnose child trophos report pharmaceutical division total consideration eur million eur million pay cash eur million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero eur million foundation medicine inc april group acquire control interest foundation medicine inc fmi publicly own company base cambridge massachusetts fmi list nasdaq stock code fmi transaction advance fmis marketleading position molecular information genomic analysis provide group unique opportunity optimise identification development novel treatment option cancer patient transaction include broad research development collaboration agreement commercial collaboration agreement aim expand global sale effort fmis current future product fmi report pharmaceutical division total cash consideration usd billion roche finance report roche group note roche group consolidate financial statement identifiable asset acquire liability assume set table pharmaceutical acquisition net asset acquire millions chf trophos fmi total intangible asset product intangible use product intangible available use cash cash equivalent defer tax liability net asset liability net identifiable asset noncontrolle interest fair value previously hold equity interest goodwill allocate foundation medicine goodwill allocate roche pharmaceutical total consideration cash contingent consideration total consideration fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate trophos fmi valuation perform independent valuer fmi account receivable comprise gross contractual amount chf million expect collectable date acquisition trophos goodwill represent control premium acquire work force synergy expect integrate acquire company group exist business goodwill expect deductible income tax purpose fmi goodwill represent strategic value roche pharmaceutical access fmis molecular information genomic analysis represent premium pay trade market price obtain control business acquire workforce expect synergy goodwill expect deductible income tax purpose noncontrolle interest fmi measure date acquisition proportionate share fmis identifiable net asset group recognise financial gain chf million fair valuing equity interest fmi hold group prior transaction gain include financial income expense directly attributable transaction cost chf million report pharmaceutical operating segment general administration expense mainly relate fmi acquisition impact trophos fmi acquisition result pharmaceutical division group material diagnostic ariosa diagnostics inc january group acquire control interest ariosa diagnostics inc ariosa privately own company base san jose california ariosa molecular diagnostic testing service provider provide highly target accurate noninvasive prenatal testing nipt service clia laboratory cellfree dna cfdna technology ariosas proprietary harmony prenatal test blood test perform early week pregnancy ariosa report diagnostic operating segment sequence business total consideration usd million usd million pay cash usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million roche finance report note roche group consolidate financial statement roche group signature diagnostic february group acquire control interest signature diagnostic signature privately own company base potsdam germany signature translational oncology genomic company develop large blood plasma tissue biobank multiple cancer include colorectal cancer lung cancer construct multicentre prospective clinical study signature report diagnostic operating segment sequence business total cash consideration eur million capp medical inc april group acquire control interest capp medical inc capp privately own company base palo alto california capp develop technology cancer screening monitor detection circulate tumour dna ctdna blood capp report diagnostic operating segment sequence business total consideration usd million usd million pay cash usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million geneweave biosciences inc august group acquire control interest geneweave biosciences inc geneweave privately own company base los gatos california geneweave focus advance clinical microbiology diagnostic solution support healthcare provider fight drugresistant bacteria geneweave solution aid impactful surveillance programme early therapy guidance successful antibiotic stewardship geneweave report diagnostic operating segment molecular diagnostic business total consideration usd million usd million pay cash usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million kapa biosystems inc november group acquire control interest kapa biosystems inc kapa privately own company base wilmington massachusetts kapa manufacturing operation cape town south africa kapa core protein engineering technology enable enzyme tailor suit specific application sample preparation nextgeneration dna rna sequence dna amplification molecular diagnostic kapa report diagnostic operating segment sequence business total cash consideration usd million identifiable asset acquire liability assume set table amount geneweave kapa provisional base preliminary information valuation asset liability subject adjustment diagnostic acquisition net asset acquire millions chf ariosa signature capp geneweave kapa total intangible asset product intangible use product intangible available use marketing intangible use cash cash equivalent defer tax liability net asset liability net identifiable asset goodwill total consideration cash contingent consideration total consideration fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate ariosa capp geneweave kapa valuation ariosa capp geneweave kapa perform independent valuer ariosa kapa account receivable comprise gross contractual amount chf million chf million respectively expect collectable date acquisition goodwill represent control premium acquire work force synergy expect integrate acquire company group exist business goodwill expect deductible income tax purpose roche finance report roche group note roche group consolidate financial statement directly attributable transaction cost chf million report diagnostic operating segment general administration expense impact ariosa signature capp geneweave kapa acquisition result diagnostic division group material acquisition acquisition net asset acquire millions chf pharmaceutical diagnostic total intangible asset product intangible use product intangible available use technology intangible use defer tax asset inventory account receivable marketable security cash cash equivalent defer tax liability net asset liability net identifiable asset goodwill total consideration cash defer consideration contingent consideration settlement preexist relationship total consideration disclose net asset acquire restate follow finalisation valuation intermune dutalys bina acquisition pharmaceutical seragon pharmaceuticals inc august group acquire control interest seragon pharmaceuticals inc seragon private company base san diego california seragon report pharmaceutical division total consideration usd million usd million pay cash usd million defer cash consideration pay february usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd billion santaris pharma september group acquire control interest santaris pharma santaris private company base near copenhagen denmark santaris report pharmaceutical division total consideration usd million usd million pay cash usd million arise contingent consideration arrangement usd million arise settlement preexist relationship contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million intermune inc september group acquire control interest intermune inc intermune publicly own company base brisbane california list nasdaq acquisition add new medicine idiopathic pulmonary fibrosis esbriet group portfolio esbriet approve fda october intermune report pharmaceutical division total consideration usd billion pay cash september group issue usd billion aggregate principal senior note finance transaction roche finance report note roche group consolidate financial statement roche group dutalys gmbh december group acquire control interest dutaly gmbh dutalys private company base vienna austria dutalys report pharmaceutical division total consideration usd million usd million pay cash usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million identifiable asset acquire liability assume set table pharmaceutical acquisition net asset acquire millions chf seragon santaris intermune dutalys total intangible asset product intangible use product intangible available use technology intangible use defer tax asset inventory account receivable marketable security cash cash equivalent defer tax liability net asset liability net identifiable asset goodwill total consideration cash defer consideration contingent consideration settlement preexist relationship total consideration disclose net asset acquire restate follow finalisation valuation intermune dutalys acquisition fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate seragon santaris intermune dutalys valuation perform independent valuer fair value intermune inventory determine base estimate selling price ordinary course business estimate cost completion sale reasonable profit margin base effort complete sell inventory intermune account receivable comprise gross contractual amount chf million goodwill represent control premium acquire work force synergy expect integrate acquire company group exist business intermune control premium represent premium pay trade market price obtain control business goodwill expect deductible income tax purpose directly attributable transaction cost chf million report pharmaceutical operating segment general administration expense mainly relate intermune acquisition month december intermune contribute revenue chf million net loss chf million result report pharmaceutical division group impact seragon santaris dutalys acquisition result material roche finance report roche group note roche group consolidate financial statement diagnostic genia technologies inc june group acquire control interest genia technologies inc genia private company base california genia report diagnostic operating segment sequence business total consideration usd million usd million pay cash usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone arise june range undiscounted outcome zero usd million iquum inc june group acquire control interest iquum inc iquum private company base massachusetts iquum report diagnostic operating segment molecular diagnostic business total consideration usd million usd million pay cash usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone arise half range undiscounted outcome zero usd million addition group acquire control interest relate intellectual property hold company cash consideration usd million bina technologies inc december group acquire control interest bina technologies inc bina private company base redwood city california bina report diagnostic operating segment sequence business total consideration usd million usd million pay cash usd million defer cash consideration pay period date control end usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million identifiable asset acquire liability assume set table diagnostic acquisition net asset acquire millions chf genia iquum bina total intangible asset product intangible use product intangible available use defer tax asset inventory cash cash equivalent defer tax liability net asset liability net identifiable asset goodwill total consideration cash defer consideration contingent consideration total consideration disclose net asset acquire restate follow finalisation valuation bina acquisition fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate genia iquum fair value intangible asset bina determine replacement cost method valuation perform independent valuer goodwill represent control premium acquire work force synergy expect integrate acquire company group exist business goodwill expect deductible income tax purpose directly attributable transaction cost chf million report diagnostic operating segment general administration expense impact genia iquum bina acquisition result report diagnostic division group material roche finance report note roche group consolidate financial statement roche group cash flow business combination acquisition net cash outflow millions chf pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration pay deferred consideration pay contingent consideration pay cash acquire company transaction cost total net cash outflow restate balance sheet december annual financial statement account intermune september dutalys december bina december acquisition provisional base preliminary information valuation asset liability valuation finalise result comparative balance sheet information december restate reconciliation balance sheet net asset acquire publish previously provisional acquisition accounting restate amount report comparative final acquisition accounting require ifrs business combination present restate roche group consolidate balance sheet select item millions chf december originally measurement publish adjustment restate goodwill intangible asset defer tax liability net liability net asset measurement adjustment table closing exchange rate december restate pharmaceutical acquisition net asset acquire select item million chf intermune dutalys originally measurement originally measurement publish adjustment restate publish adjustment restate intangible asset defer tax liability net asset liability net identifiable asset goodwill total consideration restate diagnostic acquisition net asset acquire select item millions chf bina originally measurement publish adjustment restate intangible asset defer tax liability net asset liability net identifiable asset goodwill total consideration measurement adjustment table exchange rate date control acquisition annual financial statement acquisition accounting seragon santaris acquisition provisional final change amount record december roche finance report roche group note roche group consolidate financial statement global restructuring plan group continue implementation major global restructuring plan initiate prior year notably programme diagnostic division diabete care business november pharmaceutical division announce strategic realignment manufacturing network include exit site total cost chf billion considerably high cost chf billion strategic realignment pharmaceutical division manufacturing network cost chf billion global restructuring plan cost incur millions chf diagnostic site consolidation plan total year end december global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost year end december global restructuring cost employeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost include diabete care autonomy speed restructuring plan include pharmaceutical division strategic realignment manufacturing network include plan pharmaceutical division research development strategic realignment field force reduction europe asiapacific diagnostic division september roche diabetes care announce autonomy speed initiative enable business focus diabetes care specific requirement speed process decisionmake drive efficiency total cost chf million incur mainly consultancy itrelate cost employeerelate cost spend small plan division chf million include cost relate certain project restructure apply science business roche finance report note roche group consolidate financial statement roche group site consolidation november pharmaceutical division announce strategic realignment manufacturing network include exit manufacture site clarecastle ireland legans spain segrate italy florence cost plan expect order chf billion chf billion cash plan expect run approximately position affect cost plan chf million chf million noncash writedown accelerate depreciation property plant equipment additional cost record pharmaceutical division outsource logistics rosny site france closure manufacturing site toluca mexico divestment plans nutley site track global restructuring plan total cost chf million major item chf million pharmaceutical division research development strategic realignment chf million initiative reduce field force europe asiapacific region realignment april group sell wholly own subsidiary marcadia biotech inc party loss disposal chf million note remain minor plan total chf million total cost chf million major item goodwill impairment chf million relate marcadia biotech inc acquisition significant cost include chf million relate european field force reduction pharmaceutical division specialty care unit intermune integration cost chf million cost chf million implementation global outsourcing clinical trial monitoring pharmaceutical division remain minor plan total chf million global restructuring plan summary cost incur millions chf employeerelate cost termination cost define benefit plan employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment gain loss disposal property plant equipment site closure cost total site closure cost loss divestment subsidiary total cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost roche finance report roche group note roche group consolidate financial statement global restructuring plan classification cost millions chf depreciation depreciation amortisation amortisation impairment cost total impairment cost total cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic general administration pharmaceutical diagnostic corporate total total operating segment roche pharmaceutical chugai diagnostic corporate total roche finance report note roche group consolidate financial statement roche group property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january business combination addition disposal transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january business combination addition disposal transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value classification impairment property plant equipment million chf cost sale marketing distribution research development general administration total impairment charge reimbursement receive insurance company respect impairment property plant equipment borrowing cost capitalise property plant equipment roche finance report roche group note roche group consolidate financial statement genentech property purchase option exercise genentech enter master lease agreement mla slough ssf llc slough subsequently acquire health care property lease property adjacent genentechs south san francisco site develop slough development include total building construction complete time genentech fully occupy property property lease extension option november genentech exercise purchase option contain mla acquire building land closing payment november july total usd million december group record addition land building land improvement correspond shortterm longterm liabilitie cash outflow group reclassify finance lease accounting balance previously apply building lease arrangement group lessee finance lease december capitalise cost property plant equipment finance lease chf million chf million net book value asset chf million chf million carrying value leasing obligation chf million chf million report debt note finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value minimum lease payment payment year year year total future finance charge total future minimum lease payment undiscounte operating lease group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense chf million chf million operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment roche finance report note roche group consolidate financial statement roche group leasing arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method finance lease future minimum lease receipt noncancellable lease millions chf present value minimum gross investment lease lease receipt year year year total unearned finance income unguaranteed residual value net investment lease accumulate allowance uncollectible minimum lease payment chf million chf million contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straightline basis december machinery equipment original cost chf billion chf billion net book value chf billion chf billion lease party contingent rent recognise income operating lease future minimum lease receipt noncancellable lease millions chf year year year total minimum receipt capital commitment group noncancellable capital commitment purchase construction property plant equipment totalling chf billion chf billion roche finance report roche group note roche group consolidated financial statement goodwill goodwill movement carry value asset millions chf january cost accumulate impairment net book value year end december january business combination impairment charge currency translation effect december cost accumulate impairment net book value allocate follow cashgenerating unit roche pharmaceutical foundation medicine chugai total pharmaceutical division diabetes care professional diagnostic molecular diagnostic tissue diagnostic sequence strategic goodwill hold divisional level total diagnostic division disclose note goodwill december restate follow finalisation valuation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish goodwill provide note impairment charge impairment goodwill impairment charge impairment charge total chf million record related goodwill impairment charge chf million record writeoff goodwill tissue diagnostic business area diagnostic division factor lead impairment decrease forecast cash flow follow reassessment latestage future product development return predesign phase combine additional reduction immunohistochemistry testing reimbursement laboratory business plan projection period reduce year year increase pretax discount rate impairment testing addition impairment chf million record product intangible tissue diagnostic business note goodwill impairment charge chf million record pharmaceutical division writeoff goodwill marcadia biotech inc acquisition memory acquisition arius pirame acquisition deem disposed roche finance report note roche group consolidate financial statement roche group impairment testing pharmaceutical division division operate segment cashgenerate unit test goodwill goodwill arise foundation medicine acquisition record monitor roche pharmaceutical level relate strategic development roche pharmaceutical cashgenerate unit strategic goodwill roche pharmaceutical recoverable impairment testing high value use fair value cost disposal assess value use cash flow projection base recent business plan approve management business plan include management late estimate sale volume pricing production operating cost assume significant change organisation chugai foundation medicine fair value cost disposal determined reference publicly quote share price chugai foundation medicine share business plan project year valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model data capital market include government twentyyear bond weight average tax rate calculation correspond pretax discount rate diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division recoverable impairment testing base value use cash flow projection base recent business plan approve management business plan include management late estimate sale volume pricing production operating cost assume significant change organisation business plan project year sequence business project year reflect longterm nature business valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model data capital market include government twentyyear bond weight average tax rate calculation correspond pretax discount rate sensitivity analysis management perform sensitivity analyse roche pharmaceutical diagnostic division increase discount rate combine decrease forecast cash flow chugai foundation medicine decrease publicly quote share price molecular diagnostic result sensitivity analysis demonstrate change key assumption cause carry value goodwill exceed recoverable december key assumption change result goodwill impairment chf million molecular diagnostic december roche finance report roche group note roche group consolidate financial statement intangible asset intangible asset movement carry value asset millions chf product product intangible marketing technology intangible available intangible intangible use use use use total january cost accumulate amortisation impairment net book value year end december january business combination addition transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group year end december january business combination addition divestment subsidiary transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group disclose note intangible asset december restate follow finalisation valuation net asset acquire related dutalys bina acquisition reconciliation previously publish intangible asset provide note roche finance report note roche group consolidate financial statement roche group significant intangible asset december millions chf remain operating segment net book value amortisation period product intangible use intermune acquisition roche pharmaceutical year foundation medicine acquisition roche pharmaceutical year tanox acquisition roche pharmaceutical year ariosa acquisition diagnostic year kapa acquisition diagnostic year corangeboehringer mannheim acquisition diagnostic year iquum acquisition diagnostic year product intangible available use seragon acquisition roche pharmaceutical trophos acquisition roche pharmaceutical geneweave acquisition diagnostic cmi acquisition diagnostic genia acquisition diagnostic technology intangible use dutalys acquisition roche pharmaceutical year santaris acquisition roche pharmaceutical year classification intangible asset amortisation impairment expense millions chf amortisation impairment cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic total internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful live intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination separate purchase december approximately project pharmaceutical division know decision point month certain circumstance lead impairment inherent uncertainty research development process intangible asset available use particularly risk impairment project expect result commercialise product roche finance report roche group note roche group consolidate financial statement intangible asset impairment impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment impairment charge pharmaceutical division impairment charge total chf million record relate decision stop development compound different alliance partner chf million asset concern amortise fully write decision stop collaboration project alliance partner chf million asset concern amortise fully write impairment charge pharmaceutical division impairment charge total chf million record relate clinical datum assessment development project chf million asset concern amortise fully write decision stop development compound acquire previous business combination chf million asset concern amortise fully write decision stop development compound alliance partner chf million asset concern amortise fully write reassessment project hepatitis virus hcv franchise chf million mainly negative outcome arbitration competitor asset concern amortise fully write decision stop development compound chf million asset concern amortise fully write decision stop collaboration project alliance partner chf million asset concern amortise fully write diagnostic division impairment charge total chf million record relate tissue diagnostic product intangible available use chf million factor lead impairment reassessment latestage future product development return predesign phase demonstrate feasibility quality improvement asset concern use fully write tissue diagnostic product intangible use chf million factor lead impairment decrease forecast cash flow follow reduction immunohistochemistry testing reimbursement laboratory increase asset specific pretax discount rate impairment testing asset concern amortise write estimate recoverable value chf million diabetes care technology intangible use chf million factor lead impairment decrease forecast cash flow follow change timeline future product development increase assetspecific pretax discount rate impairment testing asset concern amortise write estimate recoverable value chf million potential commitment alliance collaboration purchase agreement group party inlicense similar arrangement alliance partner intangible asset purchase agreement thirdpartie arrangement purchase agreement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration purchase agreement group current estimate future thirdparty commitment payment set table figure undiscounte riskadjuste meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business roche finance report note roche group consolidate financial statement roche group potential future thirdparty collaboration purchase payment december millions chf pharmaceutical diagnostic group year year year total inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory inventory expense cost sale total chf billion chf billion inventory writedown year result expense chf million chf million account receivable account receivable millions chf trade receivables note receivable receivables allowance doubtful account chargeback allowance total account receivable allowance doubtful account movement recognise liability million chf january additional allowance create unused amount reverse utilise year currency translation effect december bad debt expense marketing distribution total chf million expense chf million roche finance report roche group note roche group consolidate financial statement marketable security marketable security millions chf availableforsale financial asset equity security debt security money market instrument time account month investment total marketable security marketable security hold fund management purpose primarily denominate swiss franc dollar euro money market instrument contract mature year december debt security contract maturity million chf year year year total debt security cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent roche finance report note roche group consolidate financial statement roche group noncurrent asset noncurrent asset million chf availableforsale investment hold fair value availableforsale investment hold cost loan receivable longterm trade receivable restrict cash receivables total financial noncurrent asset longterm employee benefit asset total nonfinancial noncurrent asset associate total noncurrent asset availableforsale investment mainly equity investment private biotechnology company keep group strategic alliance effort unquoted equity investment classify availableforsale measure cost fair value measure reliably current asset current asset millions chf accrue interest income derivative financial instrument restrict cash receivables total financial current asset prepay expense tax recoverable asset total nonfinancial current asset total current asset receivables mainly relate royalty licensing income receivables roche finance report roche group note roche group consolidated financial statement account payable account payable million chf trade payable taxis payable dividend payable payable total account payable noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability longterm liability mainly relate accrued employee benefit longterm genentech property purchase option exercise obligation note current liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue chargeback allowance accrue royalty commission accrue liability total current liability accrue liability include shortterm genentech property purchase option exercise obligation note roche finance report note roche group consolidate financial statement roche group provision contingent liability provision movement recognise liability million chf legal environmental restructure employee provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company defer consideration contingent consideration currency translation effect december current noncurrent december year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company defer consideration contingent consideration movement currency translation effect december current noncurrent december expect outflow resource year year year year december legal provision legal provision consist number separate legal matter include claim arise trade group company nature amount timing outflow difficult predict legal expense total chf million chf million reflect recent development legal matter detail major legal case outstanding disclose roche finance report roche group note roche group consolidate financial statement environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict significant provision discount time value money material significant provision relate site nutley new jersey estimate remediation cost landfill site near grenzach germany manufacturing operation close year ago estimate remediation cost manufacturing site clarecastle ireland note restructure provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain provision discount time value money material matter pharmaceutical division significant provision relate strategic realignment manufacturing network include exit manufacturing site note research development strategic realignment field force reduction europe asiapacific region employee provision relate certain employee benefit obligation sabbatical leave longservice benefit timing cash outflow reasonably estimate base past experience provision time cash outflow nature uncertain provision relate item show table provision million chf sale return contingent consideration item total provision contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note roche finance report note roche group consolidate financial statement roche group pharmaceutical legal case accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal action relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation mdl district court middle district florida tampa division august mdl closed pendency mdl district court grant summary judgment favour hlr federal ibd case proceed affirm court appeal eleventh circuit action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county january approximately case dismiss december hlr defend approximately action involve approximately plaintiff bring federal state court personal injury allegedly result use accutane february superior court new jersey law division atlantic county hold eightday evidentiary hearing plaintiff expert testify accutane cause crohns disease february superior court bar plaintiff expert method meet requirement scientific reliability superior court enter order dismiss prejudice agreedupon list crohns disease case subject superior court february order superior court enter order grant summary judgment dismiss case file new jersey resident basis drug label adequate matter law july superior court grant hlrs motion summary judgment adequacy label post ingestion case jurisdiction superior court apply new jersey law jurisdiction grant hlrs motion dismiss approximately case alternative superior court apply home state law grant summary judgment jurisdiction deny jurisdiction resulted case dismiss plaintiff appeal decision relate crohns disease drug label december juries new jersey superior court rule favour plaintiff case assess compensatory damage total usd million case rule favour plaintiff superior court hlr process appeal case usd million case verdict reverse favour hlr usd million case usd million appeal new jersey supreme court additional trial schedule individual trial result depend variety factor include unique particular case trial result date predictive future trial result group continue defend vigorously remain personal injury case claim avastinlucentis investigation february italian antitrust authority agcm announce investigation determine roche genentech novartis enter agreement restrict competition italian market drug reference particular avastin market roche lucentis market novartis avastin lucentis different drug develop approve different therapeutic purpose contain different active pharmaceutical ingredient march agcm issue verdict allege roche novartis collude artificially differentiate avastin lucentis order foster sale lucentis italy agcm fine roche eur million novartis eur million roche appeal agcm verdict tribunale amministrativo regionale del lazio tar december tar uphold decision agcm roche strongly disagree verdict tar appeal italian ministry health notify roche spa intention seek damage relate matter july roche pay eur million fine protest avoid additional penalty fee record expense general administration fine relate interest reimburse roche win case outcome matter determine time tarceva subpoena november genentech receive subpoena department justice doj request document information relate promotion tarceva prescription product initially approve treatment locally advanced metastatic nonsmall cell lung cancer failure prior chemotherapy regiman later approve additional indication genentech cooperate associate investigation government representative present time government civil liability theory specifically genentech allegedly participate offlabel promotion tarceva cause submission false claim reimbursement civil false claim act august government close criminal investigation genentech genentech continue discussion government civil liability theory outcome matter determine time roche finance report roche group note roche group consolidate financial statement rituxan arbitration october genentech biogen idec inc file complaint california sanofiaventis deutschland gmbh sanofiaventis llc sanofiaventis inc sanofi seek declaratory judgment certain genentech product include rituxan infringe sanofis patent nos patent invalid sanofi allege rituxan genentech product infringe certain claim patent march district court rule matter law genentech biogen idec infringe assert patent claim sanofi appeal court noninfringement rule appellate court affirm district court judgment patent infringement addition october sanofi affiliate hoechst gmbh hoechst file icc international court arbitration paris request arbitration genentech relate terminate patentlicence agreement hoechst predecessor genentech pertain abovementione patent relate patent outside hoechst seek payment patent licence royalty sale certain genentech product include rituxan damage breach contract relief arbitral award september february arbitrator find genentech liable hoechst patentlicence royalty rituxan award royalty interest hoechst seek february group record royalty expense chf million net assume reimbursement portion group obligation copromotion partner hoechst initiate proceeding france germany seek enforce arbitral awards october genentech pay award royalty interest hoechst protest genentech seek annulment arbitral award proceeding initiate court appeal paris hearing proceeding june september paris court appeal stay annulment proceeding seek guidance court justice specific legal question raise genentech relate arbitral award noncompliance competition law november hoechst file notice appeal french supreme court seek review paris court appeal decision seek guidance court justice november french supreme court deny hoechst challenge decision paris court appeal refer specific legal question court justice court justice hold hear january judgment expect later outcome matter determined time average wholesale price litigation hlr roche laboratories inc rli approximately brand generic pharmaceutical company name defendant legal action relate price pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresent report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend awp action file state new jersey hlr rli vigorously defend trial date set outcome matter determine time boniva litigation hlr genentech roche affiliate collectively roche name defendant numerous legal action canada relate postmenopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause osteonecrosis jaw atypical femoral fracture december roche defend approximately action involve approximately plaintiff bring federal state court action bring court queen bench province saskatchewan canada personal injury allegedly result use boniva case early discovery stage litigation individual trial result depend variety factor include unique particular case roche vigorously defend matter outcome matter determine time ema investigation october european medicines agency ema announce start infringement procedure investigate allegation allege breach medicine safety report obligation relation centrally authorise medicine november ema announce result pharmacovigilance risk assessment committee assessment roche medicine ema find impact benefitrisk balance roche medicine confirm benefitrisk profile base available safety information ema health authority confirm medicine remain authorised change treatment advice patient healthcare professional corrective preventative action result inspection implement reinspection authority november lead certain finding roche address april ema issue report european commission summarise emas findings relation investigation july european commission issue notification ema return case file ema new period inquiry ema year adopt revise report submission european commission outcome matter determine time roche finance report note roche group consolidate financial statement roche group debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt net gain loss redemption repurchase bond note loss major debt restructuring amortisation debt discount business combination net foreign currency transaction gain loss currency translation effect december bond note commercial paper amount bank financial institution finance lease obligation borrowing total debt longterm debt shortterm debt total debt pledge group asset connection debt roche finance report roche group note roche group consolidate financial statement bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollar note fix rate note september principal usd billion isin usbc note march principal usd billion outstanding usd billion isin usuam usas note september principal usd billion isin usba note september principal usd billion isin usbb note september principal usd billion isin usbe note november principal usd billion isin usbj note march principal usd billion outstanding usd billion isin usuan usau note november principal usd billion isin usbh dollar note float rate note september principal usd billion isin usbd note september principal usd billion isin usaz euro medium term note programme fix rate note march principal gbp billion isin note march principal eur billion outstanding eur billion isin note june principal eur billion isin note march principal usd million isin note march principal eur billion outstanding eur billion isin note august principal gbp million outstanding gbp million isin note february principal eur billion isin swiss franc bond fix rate bond march principal chf billion isin bond september principal chf billion isin bond september principal chf billion isin genentech senior note senior note july principal usd billion isin usag senior note july principal usd million outstanding usd million isin usac total bond note roche finance report note roche group consolidate financial statement roche group bond note maturity millions chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond pound sterling note total unamortised discount issuance bond note february group issue eur billion fix rate note coupon euro medium term note programme note mature february list luxembourg stock exchange group receive chf million aggregate net proceed issuance sale fix note march group issue usd million fix rate note coupon euro medium term note programme note mature march list luxembourg stock exchange group receive chf million aggregate net proceed issuance sale fix note november group complete offer usd billion fix rate note coupon note mature november group receive chf million aggregate net proceed issuance sale fix note major debt restructuring september group decide major debt restructuring group raise net proceed chf million debt offering describe newly issue debt senior unsecured guarantee roche holding ltd group repurchase usd million fix rate note march usd million fix rate note march usd million fix rate genentech senior note july eur million fix rate note march major debt restructuring result loss repurchase chf million issuance bond note intermune acquisition september group finance intermune acquisition note combination group fund debt security commercial paper group raise net proceed approximately chf billion debt offering describe newly issue debt senior unsecured guarantee roche holding ltd roche finance report roche group note roche group consolidate financial statement september group complete offer dollar note receive chf million aggregate net proceed issuance sale fix float rate note term proceed note follow issuance dollar fix float rate note principal net proceed usd million chf million float rate note float rate note fix rate note fix rate note fix rate note fix rate note total major debt restructuring november group major debt restructuring group raise net proceed approximately chf billion debt offering describe newly issue debt senior unsecured guarantee roche holding ltd debt repurchase usd million fix rate genentech senior note july usd million fix rate note march major debt restructuring result loss repurchase chf million november group complete offer dollar note receive chf million aggregate net proceed issuance sale fix rate note term proceed note follow issuance dollar fix rate note principal net proceed usd million chf millions fix rate note fix rate note total redemption repurchase bond note partial redemption dollar note december group resolve exercise option early partial redemption fix rate note march march group redeem outstanding principal usd million equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow chf million plus accrue interest additional chf million loss record redemption effective interest rate note september group complete tender offer repurchase usd million fix rate note march cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note september group complete tender offer repurchase usd million fix rate note march cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note redemption pound sterling note date march group redeem fix rate note principal gbp million cash outflow chf million plus accrue interest effective interest rate note redemption genentech senior note date july group redeem fix rate senior note principal usd billion cash outflow chf million plus accrue interest effective interest rate note partial repurchase genentech senior note september group repurchase usd million fix rate senior note july cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note roche finance report note roche group consolidate financial statement roche group partial repurchase euro note november group repurchase eur million fix rate note march cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note early partial redemption dollardenominated note december group resolve exercise option early partial redemption fix rate note march group redeem outstanding principal usd million march equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow approximately usd million plus accrue interest expect redemption group revise carrying value note account change amount timing estimate cash flow revise carrying value note december usd million chf million increase carry value usd million chf million record financing cost note loss redemption effective interest rate note redemption repurchase bond note group complete early repurchase gbp million fix rate note complete early redemption usd billion fix rate note cash flow issuance redemption repurchase bond note cash inflow issuance bond note millions chf euro medium term note programme euro note euro medium term note programme dollar note dollar note total cash inflow issuance bond note cash outflow redemption repurchase bond note millions chf euro medium term note programme pound sterling note euro medium term note programme euro note dollar note total cash outflow redemption repurchase bond note commercial paper roche holdings inc commercial paper program roche holdings inc establish commercial paper program issue usd billion unsecured commercial paper note guarantee roche holding ltd second half exist committed credit line available backstop support commercial paper program change eur billion usd billion new committed credit line usd billion add total commit credit line available backstop support commercial paper program usd billion december maturity note program exceed day date issuance december unsecured commercial paper note principal usd billion average interest rate outstanding movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december roche finance report roche group note roche group consolidated financial statement amount bank financial institution amount denominate currency notably chinese renminbi argentine peso average interest rate december amount outstanding chf million chf million year equity attributable roche shareholder change equity attributable roche shareholder millions chf reserve retain share capital earning fair value hedge translation total year end december january net income recognise income statement availableforsale investment fair value gain loss take equity transfer income statement income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest december entire transfer income statement report financial income expense roche finance report note roche group consolidate financial statement roche group change equity attributable roche shareholder millions chf reserve retain share capital earning fair value hedge translation total year end december january net income recognise income statement availableforsale investment fair value gain loss take equity transfer income statement income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest december entire transfer income statement report financial income expense genentech transaction group complete purchase noncontrolle interest genentech effective march base international accounting standard separate financial statement ias consistent international financial reporting standard consolidated financial statement ifrs adopt group transaction account equity transaction consequence carrying consolidate equity group time reduce chf billion chf billion allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy roche finance report roche group note roche group consolidate financial statement share capital december authorise issue share capital roche holding ltd group parent company consist million share nominal value chf precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition shareholder group pool voting right hold share correspond share issue figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool describe note base information supply group novartis ltd basel affiliates participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend chf share nonvoting equity security chf respect business year distribution holder outstanding share nonvoting equity security total chf million chf million record retain earning board director propose dividend business year chf share nonvoting equity security approve result total distribution shareholder chf million subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security million million share nonvoting equity security total equity instrument record equity original purchase cost december fair value share chf million nonvoting equity security chf billion equity instrument hold group potential conversion obligation arise group equity compensation plan note reserve fair value reserve fair value reserve represent cumulative net change fair value availableforsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc roche finance report note roche group consolidate financial statement roche group subsidiary chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai consolidated subsidiary chugai fully consolidated subsidiary group base group interest chugai december roche relationship chugai found basic alliance licensing research collaboration agreement common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement accordance international financial reporting standard ifrs file quarterly basis tokyo stock exchange certain consolidation entry minor difference chugais standalone ifrs result result chugai consolidated roche group accordance ifrs chugai summarise financial information millions chf income statement sale royalty operating income total revenue operate profit balance sheet noncurrent asset current asset noncurrent liabilitie current liability total net asset cash flow cash flow operating activity cash flow invest activity cash flow financing activity dividend dividend distribute party hold chugai share total chf million chf million record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai roche finance report roche group note roche group consolidate financial statement license agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche rest world umbrella right agreement exclude japan south korea sign revise amend restate rest world umbrella right agreement exclude japan south korea taiwan sign august agreement roche right refusal development marketing chugais development compound market outside japan exclude south korea taiwan agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment arm length basis roche chugai follow matter upfront payment right refusal licence product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis research collaboration agreement roche chugai enter research collaboration agreement area small molecule synthetic drug research biotechnologybase drug discovery foundation medicine april group acquire control interest foundation medicine inc fmi enter investor right agreement research development collaboration agreement commercial collaboration agreement consolidate subsidiary fmi fully consolidate subsidiary group base group interest fmi december roche relationship fmi found agreement common stock fmi publicly trade list nasdaq stock code fmi fmi prepare financial statement accordance gaap file quarterly basis sec certain consolidation entry difference fmis standalone gaap result result fmi consolidated roche group accordance ifrs dividend dividend distribute party hold fmi share divestment subsidiary april group sell wholly own subsidiary marcadia biotech inc party previously announce pharmaceutical division research development reorganisation total consideration receive usd million convertible note total loss divestment chf million report global restructuring cost roche pharmaceutical operating segment show table october convertible note repay group receive usd million cash recognise gain usd million loss divestment subsidiary millions chf consideration intangible asset total net asset dispose loss divestment subsidiary roche finance report note roche group consolidate financial statement roche group noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement chugai noncontrolle interest total net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan comprehensive income net tax total comprehensive income business combination dividend noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity change noncontrolle interest equity contribution noncontrolle interest december chugai noncontrolle interest total noncontrolle interest employee benefit employee remuneration million chf wage salary social security cost define contribution plan operating expense define benefit plan equity compensation plan termination cost employee benefit employee remuneration include operating result net interest cost define benefit plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit roche finance report roche group note roche group consolidate financial statement pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan define contribution plan define contribution plan fund payment employee group fund administer party group expense plan chf million chf million asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution group major define contribution plan notably roche saving plan define benefit plan plan usually establish trust independent group fund payment group company employee case notably major define benefit plan germany plans unfunded group pay pension retire employee directly financial resource plan usually govern senior governing body board trustee typically compose employee employer representative funding plan determine local regulation independent actuarial valuation separate independent actuarial valuation semiannual update prepare accordance requirement ias use group financial statement group major pension plan locate switzerland germany total account group define benefit obligation pension plan switzerland current pension arrangement employee switzerland plan govern swiss federal occupational old age survivor disability pension act bvg group pension plan administer separate legal foundation fund regular employee company contribution final benefit contributionbase certain minimum guarantee minimum guarantee swiss plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan underfunding remedie measure increase employee company contribution lower interest rate retirement account balance reduce prospective benefit suspension early withdrawal facility pension plan group major define benefit plan close new member new employee join define contribution plan large remain define benefit plan fund pension plan include separate plan originate nutley palo alto indianapoli site small unfunded supplementary retirement plan benefit base high average annual rate earning specify period length employment plan noncontributory employee group make periodic payment plan payment group usd million usd million underfunding normally remedie additional company contribution pension plan germany group major pension arrangement germany govern occupational pension act betravg plan unfunded group pay pension retire employee directly financial resource plan noncontributory employee benefit base final salary length employment plan close new member replace new plan fund regular employee company contribution administer contractual trust agreement final benefit contributionbase minimum guarantee minimum guarantee plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan roche finance report note roche group consolidate financial statement roche group pension plan rest world represent approximately group define benefit obligation consist number small plan country large pension plan chugai independently manage chugai main pension plan united kingdom chugai plan fully describe chugais ifrs financial statement pension plan fund regular employee company contribution benefit base final salary length employment plan close new member replace define contribution plan postemployment benefit opeb plan represent approximately group define benefit obligation consist postretirement healthcare life insurance scheme mainly plan mainly unfunde contributory employee group reimburse retire employee directly financial resource group major define benefit opeb plan close new member cost plan reimbursable medicare prescription drug improvement modernization act statutory funding requirement plan group funding plan extent tax efficient payment group plan december ifrs funding status include reimbursement right fund opeb plan define benefit plan income statement millions chf post post pension employment total pension employment total plan benefit plan expense plan benefit plan expense current service cost past service income cost settlement gain loss total operating expense net interest cost define benefit plan total expense recognise income statement funding status fund group define benefit plan responsibility senior governing body board trustee sponsor employer manage base local statutory valuation follow legislation requirement respective jurisdiction plan establish qualified independent actuary carry statutory actuarial valuation regular basis actuarial assumption determine funding status statutory basis regularly assess local senior governing body funding status closely monitor corporate level unfunded plan mainly group german affiliate fully reserve pension obligation invest local affiliate operation ifrs fund status fund define benefit plan remain stable reimbursement right link postemployment medical plan represent expect reimbursement medical expenditure provide medicare prescription drug improvement modernization act roche finance report roche group note roche group consolidate financial statement define benefit plan fund status millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability report balance sheet define benefit plan asset define benefit plan liability plan asset responsibility investment strategy fund plan senior governance body board trustee asset liability study perform regularly major pension plan study examine obligation postretirement benefit plan evaluate investment strategy respect key financial measure expect return expect risk expect contribution expect funded status plan interdependent way goal assetliability study select appropriate asset allocation fund hold plan investment strategy develop optimise expect return manage risk contain fluctuation statutory fund status assetliability study include strategy match cash flow asset plan obligation group currently use annuity longevity swap manage longevity risk plan asset manage internal external asset manager actual performance continually monitor pension fund governance body closely monitor corporate level financial statement difference interest income actual return plan asset remeasurement record directly comprehensive income actual return plan asset loss chf million gain chf million recognition pension asset limit present value economic benefit available refund plan reduction future contribution plan define benefit plan fair value plan asset reimbursement right millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january interest income plan asset remeasurement plan asset currency translation effect employer contribution employee contribution benefit pay fund plan benefit pay settlement administration cost december roche finance report note roche group consolidate financial statement roche group define benefit plan composition plan asset millions chf equity security debt security property cash money market instrument investment december asset invest variety different class order maintain balance risk return follow equity debt security mainly quote market price level fair value hierarchy property mainly private commercial property fund mainly observable input level fair value hierarchy cash money market instrument mainly invest financial institution credit rating low investment mainly consist alternative mortgage commodity insurance contract risk management purpose mainly observable input level fair value hierarchy unobservable input level fair value hierarchy include fair value plan asset group share nonvoting security fair value chf million chf million debt instrument issue group fair value chf million chf million define benefit obligation define benefit obligation calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth mortality rate present value define benefit obligation determine discount estimate future cash outflow interest rate highquality corporate bond government bond countrie deep market corporate bond corporate government bond denominate currency benefit pay maturity term approximate term relate pension obligation group final salarybase define benefit pension plan germany united kingdom close new participant active employee member pension plan time close new participant continue accrue benefit final salarybase define benefit pension plan new employee join group define contribution plan new employee germany join contributionbase plan minimum guarantee define benefit pension plan switzerland final benefit contributionbase minimum guarantee remain open new employee result proportion define benefit obligation relate closed plan expect decrease future roche finance report roche group note roche group consolidate financial statement define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost remeasurement demographic assumption financial assumption experience adjustment currency translation effect movement employee contribution benefit pay fund plan benefit pay unfunded plan benefit pay settlement past service income cost settlement gain loss december composition plan active member defer vested member retire member december plan geography switzerland united states germany rest world december duration year actuarial assumption actuarial assumption financial statement base requirement set ias employee benefit unbiased mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management base advice actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate salary benefit level inflation rate cost medical benefit actuarial assumption vary base local economic social condition actuarial assumption statutory valuation differ base local legal regulatory requirement roche finance report note roche group consolidate financial statement roche group demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity rate employee turnover disability early retirement base historical behaviour group company average life expectancy assume individual age follow define benefit plan average life expectancy major scheme year male female country mortality table switzerland bvg generational table united states project germany heubeck table financial assumption base market expectation period obligation settle assumption actuarial valuation show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate salary increase expect rate pension increase expect inflation rate immediate medical cost trend rate ultimate medical cost trend rate discount rate determine reference interest rate highquality corporate bond government bond countrie deep market corporate bond expect rate salary increase base expected inflation rate adjustment reflect group late expectation longterm real salary increase expect rate pension increase generally link expected inflation rate funding status plan expect inflation rate derive look level inflation imply financial market conjunction economist price inflation forecast historic price inflation economic variable circumstance medical cost trend rate account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development sensitivity analysis measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption follow table summarise impact change assumption present value define benefit obligation define benefit plan sensitivity define benefit obligation actuarial assumption millions chf year increase life expectancy discount rate increase decrease expect inflation rate increase decrease immediate medical cost trend rate increase decrease sensitivity analysis consider change assumption time leave assumption unchanged approach show isolated effect change individual assumption account assumption relate method carry sensitivity analysis prior year roche finance report roche group note roche group consolidate financial statement cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately chf million include estimate chf million additional contribution relate define benefit plan benefit pay unfunded plan estimate approximately chf million relate german define benefit plan equity compensation plan group operate equity compensation plan include separate plan chugai foundation medicine ifrs share base payment require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense equity compensation plan roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan roche connect roche option plan bonus stock award chugai foundation medicine plan total operating expense equitysettle cashsettle roche finance report note roche group consolidate financial statement roche group cash inflow outflow equity compensation plan millions chf roche option plan exercise chugai foundation medicine exercise roche connect cost transaction equity total cash inflow outflow equitysettle equity compensation plan net transaction equity net cash outflow transaction equity mainly arise sale purchase equity instrument hold group potential conversion obligation arise group equity compensation plan note equity compensation plan roche stocksettle stock appreciation right group issue stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity security grant date exercise date roche ssar plan million ssar available issuance tenyear period right nontradable equitysettle award sevenyear duration vest phase basis year roche ssar movement number right outstanding weighted average weight average number right exercise price number right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total roche restrict stock unit plan group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance condition currently performance condition outstanding rsus december roche rsu plan million nonvoting equity security available issuance tenyear period roche rsu plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant roche finance report roche group note roche group consolidate financial statement roche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december vest transferable roche performance share plan group offer future share nonvoting equity security awards discretion board director cash equivalent certain director key senior manager nontradable equitysettle award programme currently operate annual threeyear cycle roche performance share plan psp include value adjustment equivalent sum shareholder distribution group vest period attributable number share nonvoting equity security individual award grant share nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director award result zero share non vote equity security value adjustment depend achievement performance target roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million roche connect programme enable employee worldwide certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million cost plan chf million chf million roche option plan programme country ssar award plan employee right purchase nonvoting equity security exercise price specify grant date option nontradable equity settle award sevenyear duration vest phase basis year roche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche finance report note roche group consolidate financial statement roche group roche option plan term option outstanding december option outstanding option exercisable weighted average weighted average weight average number outstanding year remain exercise price number exercisable exercise price year grant thousands contractual life chf thousand chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number award fair value award calculate grant date fair value measurement input measurement fair value grant date equity compensation plan follow fair value measurement roche stocksettle roche stock appreciation roche restrict performance share roche option right stock unit plan plan plan progressively cliff vest cliff vest progressively vest period year year year year contractual life year year number grant year thousand weight average fair value chf model binomial market pricea monte carlob binomial input option pricing model share price grant date chf exercise price chf expect volatility expect dividend yield early exercise factor expect exit rate fair value roche rsus equivalent share price date grant input parameter covariance matrix roche individual company peer group base threeyear history riskfree rate minus valuation take account define rank performance structure determine payout plan volatility determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour roche finance report roche group note roche group consolidate financial statement earning share nonvoting equity security basic earning share nonvoting equity security net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number share nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf dilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf roche finance report note roche group consolidate financial statement roche group statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense financing cost financial income expense income taxis operate profit depreciation property plant equipment amortisation intangible asset impairment goodwill impairment intangible asset impairment reversal property plant equipment operating income expense define benefit plan operate expense equitysettle equity compensation plan net income expense provision bad debt reversal expense inventory writedown inventory fair value adjustment net gain loss disposal product adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total roche finance report roche group note roche group consolidate financial statement cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity dividend pay millions chf dividend roche group shareholder dividend noncontrolle shareholder chugai dividend noncontrolle shareholder increase decrease dividend payable dividend withholding tax total significant noncash transaction significant noncash transaction contingent consideration arrangement arise business combination note genentech property purchase option exercise note roche finance report note roche group consolidate financial statement roche group risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral business planning controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director roche chugai foundation medicine appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai foundation medicine credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset account receivable december group trade receivables chf billion chf billion subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective trade receivables management maximise collection unpaid amount december group combine trade receivable balance national wholesale distributor amerisourcebergen corp mckesson corp cardinal health inc equivalent chf billion represent group consolidated trade receivables chf billion represent significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold trade receivables financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country trade receivable chf billion chf billion public private customer country group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action roche finance report roche group note roche group consolidate financial statement nature geographic location counterpartie account receivable overdue impair show table include balance national wholesalers southern europe public customer describe account receivable overdue nature geographical location counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland europe north america latin america japan asia australia oceania rest world total age account receivable impair show table age account receivable impair millions chf overdue impair overdue month overdue month overdue month overdue month overdue year total account receivable cash marketable security december group cash marketable security chf billion chf billion subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly investment marketable security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity cash shortterm time deposit subject rule limit group exposure individual financial institution rate analysis cash fix income marketable security market value chf total chf total aaarange aarange arange bbbrange bbbrange unrated total roche finance report note roche group consolidate financial statement roche group master netting agreement group enter derivative transaction collateral agreement international swap derivative association isda master netting agreement respective counterpartie order mitigate counterparty risk agreement amount owe counterparty single day respect transaction outstanding currency aggregate single net payable party isda agreement meet criterion offset balance sheet group currently enforceable right offset recognise amount right offset enforceable occurrence future event default credit event contract term december significant financial asset term renegotiate impairment loss total impairment loss availableforsale financial asset amount chf million chf million liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement december group unused committed credit line financial institution total chf billion chf billion chf billion serve backstop line commercial paper program remain undiscounted cash flow contractual maturity financial liability include estimate interest payment show table contractual maturity financial liability millions chf carry value total year year year year year end december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability year end december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability takeorpay commitments group enter contract manufacturing agreement company develop manufacturing capacity flexibility future minimum takeorpay commitment agreement total potential commitment group chf billion december mainly relate contract manufacturing agreement pharmaceutical division effect roche finance report roche group note roche group consolidate financial statement market risk market risk arise change market price mainly foreign exchange rate interest rate group financial asset financial liability affect group financial result equity valueatrisk group use valueatrisk var measure impact market risk financial instrument var indicate value range give financial instrument fluctuate preset probability result movement market price var calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate actual future gain loss associate treasury activity differ materially var analysis inherent limitation associate predict timing change interest rate foreign exchange rate equity investment price particularly period high market volatility furthermore var include effect change credit spread market risk financial instrument millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component remain largely stable foreign exchange component increase unfavourable exposure mix price component arise mainly movement equity security price increase high market value equity security hold group foreign exchange risk group use swiss franc report currency result expose movement foreign currency mainly dollar japanese yen euro objective group foreign exchange risk management activity preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group use forward contract foreign exchange option crosscurrency swap hedge transaction exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate interest rate risk group mainly raise debt fix rate basis bond note group expose movement interest rate mainly dollar swiss franc euro float rate financial instrument primary objective group interest rate management protect net interest result group use forward contract option swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure roche finance report note roche group consolidate financial statement roche group price risk price risk arise mainly movement price equity security group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment capital management group define capital manage group total capitalisation sum debt plus equity include non control interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event capitalisation report senior management group regular internal management reporting show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group net equity significantly impact genentech transaction note group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai foundation medicine note chugai foundation medicine public company objective policy process manage capital determine local management roche finance report roche group note roche group consolidate financial statement financial instrument accounting classification fair value fair value financial asset liability carry value show consolidated balance sheet follow carry value fair value financial instrument millions chf fair value total available hedge fair value loan financial carry forsale instrument designate receivables liability value fair value year end december noncurrent asset availableforsale investment financial noncurrent asset account receivable marketable security cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability year end december noncurrent asset availableforsale investment financial noncurrent asset account receivable marketable security cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability fair value bond note level calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period roche finance report note roche group consolidate financial statement roche group fair value hierarchy table analyse financial instrument carry fair value valuation method different level define follow level quote price unadjuste active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial instrument millions chf level level level total year end december marketable security equity security debt security money market instrument time account month derivative financial instrument availableforsale investment hold fair value financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value year end december marketable security equity security debt security money market instrument time account month derivative financial instrument availableforsale investment hold fair value financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument group determine level fair value follow valuation technique marketable security derivative financial instrument base valuation model use observable market datum interest rate yield curve foreign exchange rate imply volatility similar instrument measurement date availableforsale investment valuation model derive recently publish observable financial price group recognise transfer level fair value hierarchy end report period transfer occur significant transfer level level vice versa year roche finance report roche group note roche group consolidate financial statement level fair value detail determination level fair value measurement transfer level fair value hierarchy set contingent consideration arrangement millions chf january arise business combination acquire business combination utilise total unrealised gain loss include income statement unused amount reverse additional create discount unwind total gain loss include comprehensive income currency translation effect december contingent consideration arrangement group party certain contingent consideration arrangement arise business combination fair value determine consider expect payment discount present value riskadjusted average discount rate expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario significant unobservable input forecast sale performance criterion riskadjuste discount rate estimate fair value increase forecast sale performance criterion rate high riskadjuste discount rate low december total potential payment contingent consideration arrangement chf billion chf billion follow potential payment contingent consideration arrangement millions chf acquisition year acquire operating segment seragon roche pharmaceutical trophos roche pharmaceutical dutalys roche pharmaceutical santaris roche pharmaceutical geneweave diagnostic genia diagnostic ariosa diagnostic cmi diagnostic iquum diagnostic diagnostic december derivative financial instrument group enter currency swap certain nonus dollar debt instrument cash collateral agreement enter counterpartie currency swap mitigate counterparty risk follow table set carry value derivative financial instrument amount subject master netting agreement roche finance report note roche group consolidate financial statement roche group derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative carry value derivative financial instrument derivative subject master netting agreement collateral arrangement net collateral arrangement fair value currency swap decrease mainly weak euro compare dollar result cash deliver group counterpartie movement cash collateral receivable accrue liability millions chf january net cash deliver group december hedge accounting december group follow cash flow hedge fair value hedge designate qualifying hedge relationship cash flow hedge group enter crosscurrency swap hedge foreign exchange interest rate risk bond note issue group denominate euro pound sterling december instrument record net fair value liability chf million chf million ineffective portion chugai enter foreign exchange forward contract hedge foreign translation exposure swiss franc dollar december instrument record fair value liability chf million chf million ineffective portion expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table expect cash flow qualify cash flow hedge millions chf total year year total year year cash inflow cash outflow total cash inflow outflow roche finance report roche group note roche group consolidate financial statement undiscounte cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity expect cash flow qualify cash flow hedge impact profit loss million chf total year year total year year cash inflow cash outflow total cash inflow outflow change hedge reserve equity show note fair value hedge group enter interest rate swap hedge fixedterm debt instrument december instrument record fair value liability chf million chf million fair value asset chf million chf million gain chf million record interest rate swap gain chf million fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument december group forward contract manage risk market fluctuation equity investment biotechnology company forward contract record fair value liability chf million december hedge equity investment sell forward contract settle result loss forward contract chf million loss chf million loss forward contract offset gain sale hedge equity investment record net gain sale equity security note net investment hedge group net investment hedge relate party control shareholder share capital roche holding ltd group parent company consist bearer share december base information supply group shareholder group pool voting right own share represent issue share group consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool andr hoffmann andreas oeri members board director roche holding ltd hoffmann receive remuneration totalling chf chf oeri receive remuneration totalling chf chf transaction group individual member shareholder group exception jrg duschmal work postdoc roche subsidiary associate list major group subsidiary associate include note transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associate roche finance report note roche group consolidate financial statement roche group key management personnel total remuneration key management personnel chf million chf million member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee franz members corporate executive committee roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee member corporate executive committee participate certain equity compensation plan describe term vest condition fair value award disclose note new member corporate executive committee include table calendar year join cec similarly members corporate executive committee retire way year include calendar year leave cec remuneration member board director corporate executive committee millions chf salary include cashsettle bonus bonus stock award social security cost pension postemployment benefit equity compensation plan board fee employee benefit total purpose remuneration disclosure value equity compensation plan include bonus stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition detailed disclosure executive remuneration require swiss law include remuneration report include annual report page disclosure value equity compensation plan include bonus stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration member board director corporate executive committee ifrs basis table deduct bonus stock award ifrs basis equity compensation plan ifrs basis add bonus stock award swiss legal basis equity compensation plan swiss legal basis total remuneration member board director corporate executive committee swiss legal basis include social security cost board director annual report corporate executive committee page annual report roche finance report roche group note roche group consolidate financial statement bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number award fair value award calculate grant date equity compensation plan member corporate executive committee receive equity compensation show follow table number right option award grant member corporate executive committee roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan contribution pay member corporate executive committee millions chf roche connect transaction member board director corporate executive committee pension totalling chf million pay group corporate executive committee member chf million subsequent retirement member board director humer receive chf million advisory capacity chairman board define benefit plan transaction group define benefit plan employee group describe note roche finance report note roche group consolidate financial statement roche group subsidiary associates list company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich valor share valor genussschein isin share isin genussschein market capitalisation chf japan chugai pharmaceutical ltd tokyo jpy stock exchange tokyo isin market capitalisation jpy united states foundation medicine inc cambridge usd stock exchange nasdaq stock code fmi market capitalisation usd nonliste company share capital equity interest country company city millions algeria roche algrie spa hydra dzd argentina productos roche qumica industrial tigre ar vanguardia productos farmacuticos vanprofarma buenos aire ars australia roche diabetes care australia pty limited bella vista aud roche diagnostics australia pty limited castle hill aud roche product pty limited dee aud austria dutalys gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostic gmbh vienna eur azerbaijan roche azerbaijan llc baku azn bangladesh roche bangladesh limited dhaka bdt belarus fllc roche product limit minsk byr belgium roche brussels eur roche diagnostic belgium brussels eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche product limit hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico farmacuticos paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd john cad chile roche chile limitada santiago chile clp china roche china holding ltd shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche diagnostic suzhou limited suzhou cny roche hong kong limited hong kong hkd roche center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city millions colombia producto roche bogot cop costa rica roche servicios heredia usd cte divoire roche cte divoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche medicinalvarer kemikalier hvidovre dkk roche diagnostic hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic producto roche dominicana santo domingo dop ecuador roche ecuador quito usd egypt roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp rodiagnostic egypt trading sae giza egp salvador productos roche salvador san salvador svc estonia roche eesti tallinn eur finland roche diagnostic espoo eur roche espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostic france sas meylan eur roche sas boulognebillancourt eur trophos marseille eur ventana medical systems sas illkirch eur georgia roche georgia llc tbilisi gel germany ascur versicherungsvermittlung gmbh grenzachwyhlen eur galenus mannheim pharma gmbh mannheim eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen eur roche diabete care gmbh mannheim eur roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche mtm laboratories mannheim eur roche pharma grenzachwyhlen eur roche pvt gmbh waiblingen eur roche real estate service mannheim gmbh mannheim eur signature diagnostic gmbh potsdam eur swisslab gmbh berlin eur verum diagnostica gmbh munich eur ghana roche product ghana limit accra ghs greece roche hellas athens eur roche diagnostic hellas athens eur guatemala producto roche guatemala guatemala gtq honduras producto roche honduras tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche product india pvt ltd mumbai inr indonesia roche indonesia jakarta idr iran roche par ltd tehran irr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit il roche pharmaceutical israel ltd petach tikva il italy roche diagnostic spa monza eur roche spa monza eur japan roche diagnostic tokyo jpy jordan hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius ltl macedonia roche makedonija dooel skopje mkd malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd petale jaya myr syntex pharmaceutical sdn bhd kuala lumpur myr mauritius roche product mauritius limited quatre borne mur mexico producto roche mexico city mxn roche servicios mxico mexico city mxn roche finance report note roche group consolidate financial statement roche group share capital equity interest country company city million moldova roche product limit srl chisinau mdl morocco roche casablanca mad myanmar roche myanmar company limited yangon usd netherland kapa biosystem amsterdam usd roche diabete care nederland almere eur roche diagnostic nederland almere eur roche finance europe woerden eur roche nederland woerden eur roche pharmholde woerden eur new zealand roche diagnostic limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua managua nio nigeria roche product limited lagos ngn norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd panama producto roche panam panama city pab producto roche interamericana panama city usd peru producto roche qumica farmacutica lima pen roche farma peru lima pen philippine roche philippines inc taguig city php poland roche diabetes care polska warsaw pln roche diagnostic polska warsaw pln roche polska warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostic rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druzba doo ljubljana eur south africa kapa biosystem pty ltd cape town zar roche product proprietary limited illovo zar south korea roche diagnostics korea ltd seoul krw roche korea company ltd seoul krw spain andreu roche madrid eur roche diabetes care spain barcelona eur roche diagnostic barcelona eur roche farma madrid eur sri lanka roche product colombo private limited colombo lkr sweden roche stockholm sek roche diagnostic scandinavia bromma sek switzerland biopharm basel chf hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf intermune international basel chf museum tinguely basel chf phaor basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen basel chf roche diabetes care ltd rotkreuz chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex pharm basel chf tavero basel chf roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city million taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie tunis tnd turkey roche diagnostic turkey anonim sirketi istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah united arab emirate roche diagnostic middle east fzco dubai ae roche middle east fzco dubai ae united kingdom intermune holding limit welwyn garden city gbp intermune limited welwyn garden city gbp intermune limited welwyn garden city gbp intermune bristol limited welwyn garden city gbp kapa biosystems ltd london gbp pirame limited welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostics ltd burgess hill gbp roche hold limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation little fall usd adheron therapeutics inc wilmington usd anadys pharmaceuticals inc south san francisco usd ariosa diagnostics inc san jose usd bina technologies inc belmont usd bioveris corporation indianapoli usd genentech usa inc south san francisco usd genentech inc south san francisco usd geneweave biosciences inc los gatos usd genia technologies inc mountain view usd hlr consumer health inc little fall usd hoffmannla roche inc little falls usd igen international inc pleasanton usd intermune inc south san francisco usd iquum inc marlborough usd kapa biosystem inc wilmington usd memory pharmaceutical corp little fall usd roche carolina inc florence usd roche diabete care inc indianapoli usd roche diagnostic corporation indianapoli usd roche diagnostic hematology inc westborough usd roche diagnostic operation inc indianapoli usd roche health solution inc fisher usd roche holdings inc south san francisco usd roche laboratory inc little fall usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche palo alto llc south san francisco usd roche tcrc inc new york usd seragon pharmaceuticals inc south san francisco usd spring bioscience corp pleasanton usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch montevideo uyu venezuela producto roche caracas vef vietnam roche vietnam ltd chi minh city usd share capital local currency unit roche finance report note roche group consolidate financial statement roche group significant accounting policy consolidation policy subsidiary company include structured entity group control group control entity group expose right variable return involvement entity ability affect return power entity company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control associate company group exercise power exercise significant influence control account equity method segment report purpose segment report group corporate executive committee cec consider group chief operating decision maker determination group operate segment base organisation unit information report cec regular basis information provide basis segment revenue profit disclosure report note geographic analysis base location customer select segment balance sheet information routinely provide cec transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation annual financial statement present swiss franc group company use local currency functional currency certain group company use currency dollar swiss franc euro functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer comprehensive income consolidation asset liability group company functional currency swiss franc translate swiss franc yearend rate exchange income statement statement cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly comprehensive income roche finance report roche group note roche group consolidate financial statement revenue sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risk reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid similar rebate country deduct sale record accrue liability provision deduction account receivable estimate base analyse exist contractual legislatively mandate obligation historical trend group experience circumstance level sale return revenue reliably measure sale recognise right return expire generally prescription product patient revenue record earn service perform single transaction split separately identifiable component reflect substance transaction necessary conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation achievement normal production capacity expense incur research development internal research development activity expense incur follow internal research cost incur purpose gain new scientific technical knowledge understand internal development cost incur application research finding knowledge plan develop new product commercial production development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation intangible asset meet prior obtain marketing approval regulatory authority major market postmarkete study regulatory approval phase cost pharmaceutical business generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure acquire inprocess research development resource obtain inlicense arrangement business combination separate asset purchase capitalise intangible asset acquire asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy subsequent internal research development cost incur post acquisition treat way internal research development cost research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset license milestone upfront receipt royalty income recognise accrual basis accordance substance respective licensing agreement collectability royalty reasonably assure royalty recognise revenue cash receive certain group company receive upfront milestone similar payment party relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing obligation roche finance report note roche group consolidate financial statement roche group employee benefit shortterm employee benefit include wage salary social security contribution pay annual leave sick leave profit share bonus nonmonetary benefit current employee cost recognise operating result employee render associate service group recognise liability profit share bonus contractually oblige past practice create constructive obligation longterm employee benefit include longservice sabbatical leave longservice benefit longterm disability benefit expect cost benefit accrue period employment change carry value longterm employee benefit liability recognise operating result termination benefit payable employment terminate group normal retirement date employee accept voluntary redundancy exchange benefit termination cost recognise early group long withdraw offer benefit group recognise related restructuring cost pension postemployment benefit define contribution plan group contribution recognise operating result employee render associated service prepay contribution recognise asset extent cash refund reduction future payment available define benefit plan liability recognise balance sheet present value define benefit obligation fair value plan asset change net define benefit liability recognise occur follow recognise income statement current service cost charge appropriate income statement head operating result past service cost include curtailment gain loss recognise immediately general administration operating result settlement gain loss recognise general administration operating result net interest net define benefit liability recognise financing cost recognise comprehensive income actuarial gain loss arise experience adjustment difference previous assumption actually occur change actuarial assumption return plan asset exclude amount include net interest net define benefit liability change limit recognition plan asset exclude amount include net interest net define benefit liability net interest net define benefit liability comprise interest income plan asset interest cost define benefit obligation interest effect limit recognition pension asset net interest calculate discount rate calculate define benefit obligation apply net define liability start period take account change contribution benefit payment pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan equity compensation plan fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity roche finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee finance lease exist substantially risk reward ownership transfer group finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt finance lease asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method operating lease exist substantially risk reward ownership transfer group payment operating lease charge income straightline basis period lease group lessor certain asset mainly diagnostic instrument lease party finance operating lease arrangement finance lease asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method operating lease asset report property plant equipment lease income operating lease recognise lease term straightline basis business combination business combination account acquisition method accounting date acquisition group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest acquire business consideration transfer measure fair value date acquisition group acquire ownership acquire business noncontrolle interest record fair value proportion fair value acquire net asset attributable noncontrolle interest directly attributable acquisitionrelated cost expense incur general administration expense goodwill goodwill arise business combination excess consideration transfer acquire business underlie fair value net identify asset acquire goodwill amortise test impairment annually occurrence indication impairment roche finance report note roche group consolidate financial statement roche group intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination initially record fair value available use intangible asset amortise straight line basis useful life intangible asset review impairment reporting date estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate useful life major class amortisable intangible asset follow product intangible use year marketing intangible use year technology intangible use year impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost disposal value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm interest rate impairment loss arise useful life asset review necessary future depreciation amortisation charge accelerate impairment loss subsequently decrease decrease relate objectively event occurring impairment recognise previously recognise impairment loss reverse income statement impairment reversal impairment goodwill goodwill assess impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit recoverable cashgenerate unit high fair value cost disposal value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss acquire business include cash generating unit permanently cease operate treat disposal business separately identifiable goodwill generate initial acquisition business factor goodwill entirely unrelated continue operation cashgenerating unit goodwill deem dispose fully impair impairment testing methodology describe note inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record objective evidence group able collect amount estimate base specific indicator age customer balance specific credit circumstance group historical experience take account economic condition expense doubtful trade receivables recognise marketing distribution expenses trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience roche finance report roche group note roche group consolidate financial statement cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash equivalent readily convertible know amount cash subject insignificant risk change fair value maturity month date acquisition provision contingency provision recognise legal constructive obligation incur probably lead outflow resource reliably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise discount time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available financial instrument financial instrument classify follow category disclose note availableforsale nonderivative financial asset designate classified financial asset category availableforsale asset initially record subsequently carry fair value change fair value record comprehensive income impairment interest foreign exchange component investment derecognise cumulative gain loss equity reclassify financial income expense availableforsale asset mainly comprise marketable security fair value hedge instrument derivative financial instrument manage exposure foreign currency interest rate equity market credit risk derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense fair value designate nonderivative financial instrument designate fair value profit loss initial recognition designate fair value instrument initially record subsequently carry fair value change fair value record income statement designate fair value instrument mainly comprise contingent consideration liability change fair value record general administration operating result loan receivables nonderivative financial asset fix determinable payment quote active market loan receivables initially record fair value subsequently carry amortise cost effective interest rate method impairment loss loan receivables mainly comprise account receivable cash cash equivalent financial liability nonderivative financial liability financial liability initially record fair value subsequently carry amortise cost effective interest rate method financial liability mainly comprise debt trade payable financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer financial liability derecognise contractual obligation discharge cancel expire roche finance report note roche group consolidate financial statement roche group impairment financial asset financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty available forsale equity security market value original cost market value original cost sustain sixmonth period consider impaired financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry comprehensive income difference original cost fair value impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly comprehensive income hedge accounting group use derivative manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forwards contract option group generally limit use hedge account certain significant transaction qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income expense cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge instrument record fair value effective portion hedge include comprehensive income ineffective portion report financial income expense hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial item cumulative change fair value hedge instrument record comprehensive income include initial carrying value nonfinancial item date recognition cash flow hedge cumulative change fair value hedge instrument record comprehensive income include financial income expense forecast transaction affect net income fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income expense debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future roche finance report roche group note roche group consolidated financial statement defer tax asset liability recognise temporary difference tax basis asset liability carry value defer tax asset recognise extent probable future taxable profit available unused tax loss utilise current defer tax asset liability offset income taxis levy taxation authority legally enforceable right offset defer taxis determine base currently enact tax rate applicable tax jurisdiction group operate equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument hold group potential conversion obligation arise group equity compensation plan change accounting policy group implement minor amendment exist standard interpretation material impact group overall result financial position future new revise standard group currently assess potential impact new revise standard interpretation mandatory january group apply base analysis date group anticipate material impact group overall result financial position group assess new revise standard mandatory notably ifrs financial instrument ifrs revenue contract customer ifrs lease roche finance report report roche management internal control financial reporting roche group report roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework version issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set christoph franz alan hippe chairman board directors chief financial officer basel january roche finance report roche group report statutory auditor general meeting shareholder roche holding ltd basel report statutory auditor general meeting shareholder roche holding ltd basel report statutory auditor consolidated financial statement statutory auditor audit accompany consolidated financial statement roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flow statement change equity note page year end december board director responsibility board director responsible preparation consolidate financial statement accordance international financial reporting standard ifrs requirement swiss law responsibility include design implement maintain internal control system relevant preparation consolidate financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion consolidated financial statement base audit conduct audit accordance swiss law swiss auditing standard international standard auditing standard require plan perform audit obtain reasonable assurance consolidated financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure consolidated financial statement procedure select depend auditor judgement include assessment risk material misstatement consolidated financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation consolidated financial statement order design audit procedure appropriate circumstance audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation consolidated financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion consolidate financial statement year end december true fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ian starkey marc ziegler license audit expert auditor charge license audit expert basel january roche finance report report independent auditor internal control financial reporting board director roche holding ltd basel roche group report independent auditor internal control financial reporting board director roche holding ltd basel report independent auditor internal control financial reporting examine roche group system internal control financial reporting december base criterion establish internal control integrate framework version issue committee sponsor organization treadway commission coso board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control financial reporting responsibility express opinion company internal control financial reporting base examination entity internal control financial reporting process effect entitys board director management personnel design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection unauthorised acquisition use disposition entitys asset material effect entitys financial statement conduct examination accordance international standard assurance engagement isae standard require plan perform examination obtain reasonable assurance effective internal control financial reporting maintain material respect examination include obtain understand internal control financial reporting testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe examination provide reasonable basis opinion inherent limitation internal control financial reporting include possibility management override control misstatement error fraud occur detect projection evaluation internal control financial reporting future period subject risk internal control inadequate change condition degree compliance policy procedure deteriorate opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework version issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg ian starkey marc ziegler license audit expert auditor charge license audit expert basel january roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply retrospectively dividend propose board director roche finance report multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply retrospectively dividend propose board director roche finance report roche group multiyear overview supplementary information sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report multiyear overview supplementary information roche group supplementary core result ep information group basic diluted earning share give note annual financial statement allow transparent assessment actual result underlie performance business income statement group operating result division show ifrs core basis core result concept internal management business base ifrs result follow adjustment global restructuring plan note exclude amortisation impairment intangible asset note impairment goodwill note exclude acquisition accounting onetime impact alliance arrangement business combination financial review exclude discontinued operation currently exclude legal environmental expense financial review exclude global issue outside healthcare sector group control currently exclude material onetime treasury item major debt restructuring note exclude pension plan settlement note exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm group ifrs result include divisional breakdown reconcile core result table calculation core eps give table additional commentary adjustment item give financial review roche finance report roche group multiyear overview supplementary information core result reconciliation million chf alliance normali global intangible business legal major debt pension sation restruc amorti intangible combi environ restruc plan ecp tax ifrs ture sation impairment nation mental ture settlement benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result reconciliation million chf alliance normali global intangible business legal major debt sation restruc amorti intangible combi environ restruc ecp tax ifrs ture sation impairment nation mental ture benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest roche finance report multiyear overview supplementary information roche group divisional core result reconciliation million chf alliance global intangible business legal pension restruc amorti intangible combi environ plan ifrs ture sation impairment nation mental settlement core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation million chf alliance global intangible business legal restruc amorti intangible combi environ ifrs ture sation impairment nation mental core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary information core ep basic core net income attributable roche shareholder chf million weight average number share nonvoting equity security issue million core earning share basic chf core ep diluted core net income attributable roche shareholder chf million increase noncontrolle interest share core net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue calculate diluted earning share million core earning share dilute chf roche finance report multiyear overview supplementary information roche group supplementary operating free cash flow information divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset total adjustment add expense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct utilisation provision proceed disposal total operating profit cash adjustment ebitda core operate profit depreciation impairment property plant equipment core basis ebitda margin sale roche finance report roche group multiyear overview supplementary information supplementary balance sheet information net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset disclose note goodwill intangible asset pharmaceutical diagnostic division defer tax net asset group december restate follow finalisation valuation net asset acquire related intermune dutalys bina acquisition reconciliation previously publish balance sheet provide note roche finance report multiyear overview supplementary information roche group nongaap measure financial information include financial review include certain nongaap measure accounting measure define ifrs particular core result net work capital net operating asset free cash flow constant exchange rate nongaap measure instead consider alternative group consolidated financial result base ifrs nongaap measure comparable similarly title measure disclose company core result core result allow assessment group actual result define ifrs underlie performance business core result concept explain net working capital net working capital assess group efficiency utilise asset shortterm liquidity net trade work capital calculate trade receivables inventory minus trade payable net work capital calculate net trade work capital adjust receivables payable net operating asset net operating asset allow assessment group operate performance business independently finance tax activity net operating asset calculate property plant equipment goodwill intangible asset net work capital longterm net operating asset minus provision free cash flow free cash flow assess group ability generate cash require conduct maintain operation operate free cash flow calculate base ifrs operating profit adjust certain cash item movement net work capital capital expenditure investment property plant equipment intangible asset free cash flow calculate operate free cash flow adjust treasury activity taxis pay dividend pay constant exchange rate certain percentage change financial review calculate constant exchange rate cer allow assessment group financial performance effect exchange rate fluctuation eliminate percentage change constant exchange rate calculate simulation reconsolidate current report period prior period number constant currency exchange rate equal average exchange rate prior year example cer change line item equivalent calculate average exchange rate year end december line item line item subsequently calculate change percent respect recalculate number roche finance report roche group roche security roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july information table restate change ratio adr effective january change ratio adr effective january change ratio adr effective february roche finance report roche security roche group number share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total number share nonvoting equity security genussscheine hold total issue datum share nonvoting equity security chf earning basic earning dilute core earning basic core earning dilute equity attributable roche shareholder dividend stock price share open high low yearend stock price nonvoting equity security genussschein open high low yearend market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price dividend propose board director ticker symbol share nonvoting equity security american depositary receipt adr swiss exchange rog bloomberg rog rhhby reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statement note financial statement summary significant accounting policy ignificant shareholder hareholders equity ulltime equivalent contingent liability board executive shareholding appropriation available earning report statutory auditor general meeting shareholder roche holding ltd basel roche finance report financial statement roche holding ltd basel financial statement balance sheet millions chf december december current asset cash cash equivalent marketable security account receivable group company shortterm loan group company current receivables total current asset noncurrent asset longterm loan group company investment total noncurrent asset total asset shortterm liability account payable group company shortterm interestbeare liability group company shortterm liability shortterm provision total shortterm liability longterm liability provision total longterm liability total liability shareholder equity share capital nonvoting equity security genussscheine legal retain earning general legal retain earning voluntary reserve retain earning free reserve special reserve available earning balance bring forward previous year net income year equity instrument total shareholder equity total shareholder equity liability presentation balance sheet december adjust follow change new law account financial reporting contain title swiss code obligation adopt january pro memoria nonvoting equity security nominal value roche finance report roche holding ltd basel financial statement income statement millions chf year end december income income investment dividend income financial income interest income loan group company income marketable security guarantee fee income group company income total income expense administration expense expense financial expense direct taxis total expense net income presentation income statement year end december adjust follow change new law account financial reporting contain title swiss code obligation adopt january roche finance report note financial statement roche holding ltd basel note financial statement summary significant accounting policy basis preparation financial statement roche holding ltd basel company prepare accordance provision swiss law accounting financial report title swiss code obligation prescribe law significant accounting principle apply describe change new law account financial reporting contain title swiss code obligation adopt january comparative financial information adjust company prepare consolidated financial statement accordance recognise accounting standard international financial reporting standard accordance company decide forgo present additional information audit fee note cash flow statement valuation method translation foreign currency marketable security report low cost market value financial asset include investment report cost appropriate writedown equity instrument recognise cost deduct equity time purchase equity instrument sell gain loss recognise income statement asset liability denominate foreign currency translate swiss franc yearend rate exchange investment translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer investment major direct indirect investment company list note roche group annual financial statement ownership interest equal voting right taxis direct taxis include corporate income capital taxis shareholder equity share capital previous year share capital amount chf million share capital consist bearer share nominal value chf include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate roche finance report roche holding ltd basel note financial statement equity instrument company purchase roche share company sell roche share roche share average sale price chf share chf share net gain chf million net gain chf million dividend income amount chf million chf million december company hold remain roche share roche share cost chf million chf million deduct equity number equity instrument hold company subsidiary exclude foundation meet definition requirement article roche group annual financial statement entity mainly foundation include consolidation qualify subsidiary article movement recognise amount million chf legal voluntary reserve retain earning share retain free special available equity total capital earning reserve reserve earning instrument equity january net income dividend transaction equity instrument december net income dividend transaction equity instrument december net income dividend transaction equity instrument december movement recognise amount equity adjust follow change new law account financial reporting contain title swiss code obligation adopt january contingent liability guarantee company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december chf billion chf billion describe note roche group annual financial statement significant shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company roche finance report note financial statement roche holding ltd basel control shareholder december base information supply group shareholder group pool voting right own share represent issue share group consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool december base information supply group share share own novartis ltd basel include affiliate thereof participation fulltime equivalent annual average number fulltime equivalent exceed people board executive shareholding board director director andr hoffmann andreas oeri certain member founder family closely associate belong shareholder group pool voting right end group hold share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table annual general meeting march dame deanne julius professor beatrice weder mauro stand reelection mrs julie brown claudia sssmuth dyckerhoff nominate election new member board director shareholding member board director nonvoting equity security share genussscheine franz hoffmann baschera bell bulcke julius lifton oeri poussot schwan voser weder mauro total include share hold shareholder group pool voting right equity compensation award roche option plan ssar rsus roche performance share plan member corporate executive committee schwans shareholdings disclose table roche finance report roche holding ltd basel note financial statement corporate executive committee member corporate executive committee person closely associate hold share nonvoting equity security show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan ayyoubi diggelmann hippe keller oday total equity compensation award roche option plan ssar rsus roche performance share plan close relative keller hold roche share roche share december members corporate executive committee hold roche option plan award rop stocksettle stock appreciation right ssar show table term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page rop ssar award hold december year issue total schwan ayyoubi diggelmann hippe keller oday total cec strike price chf expiry date mar mar mar mar feb feb feb december members corporate executive committee hold restrict stock unit rsus show table term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page rsu award allocate individually remuneration committee discretion vest recipient year nonvoting equity security remain block year rsu award hold december year issue total schwan ayyoubi diggelmann hippe keller oday total cec roche finance report note financial statement roche holding ltd basel december members corporate executive committee show table hold psp award psp performance cycle term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page award result zero nonvoting equity security share value adjustment depend achievement performance target discretion board director vest nonvoting equity security share remain block year end cycle performance target achieve accordingly participant receive originally target nonvoting equity security total target number award outstanding performance cycle december show table roche performance share plan award hold december psp psp schwan ayyoubi diggelmann hippe keller oday total cec allocation date feb feb information relate number value right option award grant employee roche group member board director corporate executive committee company disclose note note roche group annual financial statement roche finance report roche holding ltd basel appropriation available earning appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year total appropriation available earning carry forward account roche finance report report statutory auditor general meeting shareholder roche holding ltd basel roche holding ltd basel report statutory auditor general meeting shareholder roche holding ltd basel report statutory auditor financial statement statutory auditor audit accompany financial statement roche holding ltd comprise balance sheet income statement note page year end december board director responsibility board director responsible preparation financial statement accordance requirement swiss law company article incorporation responsibility include design implement maintain internal control system relevant preparation financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion financial statement base audit conduct audit accordance swiss law swiss auditing standard standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure financial statement procedure select depend auditor judgement include assessment risk material misstatement financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation financial statement order design audit procedure appropriate circumstance purpose express opinion effectiveness entity internal control system audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion financial statement year end december comply swiss law company article incorporation report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg ian starkey marc ziegler license audit expert auditor charge license audit expert basel january roche finance report publish cautionary statement forwardlooke statement hoffmannla roche ltd annual report contain certain forwardlooking statement group communication forwardlooke statement identify word basel switzerland believe expect anticipate project intend tel seek estimate future similar expression wwwrochecom discussion thing strategy goal plan intention factor cause actual result differ order publication materially future reflect forwardlooke tel statement contain annual report fax pricing product initiative competitor legislative email baselwebmasterrochecom regulatory development economic condition delay inability obtain regulatory approval bring product medium relation market fluctuation currency exchange rate general basel switzerland financial market condition uncertaintie discovery tel development marketing new product new use exist email rochemediarelationsrochecom product include limitation negative result clinical trial research project unexpected effect pipeline investor relation market product increase government pricing pressure basel switzerland interruption production loss inability obtain tel adequate protection intellectual property right litigation email investorrelationsrochecom loss key executive employee adverse publicity news coverage corporate sustainability committee tel statement earning share growth profit email corporatesustainabilityrochecom forecast interpret mean roche earning earning share subsequent period annual general meeting necessarily match exceed historical publish earning march earning share roche trademark mention enjoy legal protection link thirdparty page provide convenience express opinion content thirdparty page expressly disclaim liability thirdparty information use roche finance report publish german english case doubt difference interpretation english version shall prevail german text report consist actual annual report finance report contain annual report annual financial statement consolidate financial statement article incorporation sense management report print nonchlorine bleach fsccertified paperfhoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche finance report finance report